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ABSTRACT  
Background: The incidence of tuberculosis in South Africa last measured at 834 in 2015 as 
reported by the World Bank. Out of these cases, only 54% cured and 13% of patients stop 
taking treatment. In Pretoria, Gauteng, comprehensive TB services are available in 87% of 
clinics and all these clinics offer the Directly Observed Treatment Short-course (DOTS) 
programme and help to diagnose TB and trace contacts. However, the average Pretoria 
district DOTS coverage has decreased from 88.8% to 84.7% in the last few years. The health 
district's cure rate as at 2012 is 61%, and its average rate of successful treatment of all new 
smear positive cases is 66% since 2005.  
Certain factors that determine patients’ adherence towards TB treatment have been identified 
to include demographic, psychosocial and health system related factors. However, the WHO 
identified factors responsible for or predisposing patients to discontinue the DOTS 
programme have not been investigated in the study setting.  
Aim: The aim of this study was to assess the determinants of adherence to DOTS therapy 
amongst TB patients who commenced TB treatment at the TB clinic of a district hospital 
during April – June 2014. 
  
Methodology: A quantitative study was conducted using a descriptive cross-sectional design. 
An inclusive sample was drawn from adults in the DOTS programme receiving first line 
treatment during the 6-month period prior to commencement of the research. The calculated 
sample size was 234 individuals. The data collection tools included a questionnaire, 2-day 
recall and 30-day recall instruments and pill counts. Data were analysed using EPI info 
version 7 which included descriptive statistics to measure level of adherence. Associations 
between identified factors and adherence to TB treatment were also determined.    
Results: The final sample size was 80 participants of which 76% were male. The mean 
composite adherence rate was found to be 94% while the proportion of the patients who 
achieved adherence of 95% and above was 75%. Identified barriers to adherence include 
forgetfulness, lack of transport fare on clinic appointment days, patients not feeling well and 
so were not strong enough to attend clinic appointments. On the other hand, the role of 
treatment supporters and counseling were found to have a positive impact on adherence to 
DOT in this setting. The use of reminders such as cell phones and alarm-radios were also 
identified as facilitators to adherence. Patients’ knowledge of consequences for not taking 
iii 
 
medications as prescribed, which is closely linked with counseling, was found to be 
significantly associated with adherence in this study.  
Education status of participants was found to be significantly associated with adherence to 
DOTS (p = 0.01), when considering the pharmacy refill pill count as the adherence measure. 
Significant association was found between DOTS treatment regimens and 30-day recall 
adherence measures (p = 0.002). Significant association was also found for medication side 
effects and the adherence measures of 2-day recall, 30-day recall and pill count with p = 0.04; 
p = 0.03; p = 0.05 respectively There were significant associations between age and 
adherence with two of the adherence measures (30-day recall and pill count) at p = 0.002 and 
p = 0.003 level of significance respectively. Significant association was observed between 
duration of DOTS treatment when dichotomised using the mean treatment period (17 weeks) 
as the cut-off point and any of the adherence measures.  
Conclusion: The factors identified in this study can be classified into patient related factors, 
economic factors, social factors and health care workers and health system related factors. 
Furthermore, the factors at these different levels impact on one another and their 
improvements need to be made at all these levels to address the challenges facing TB patients 
to achieve optimal treatment adherence. This study is the first study of its kind in the study 
location and the findings have provided useful baseline data on the adherence rates and some 
insights into the major factors that affect adherence among patients on DOTS at a Pretoria 
West District Hospital. However further qualitative and quantitative studies are required to 
explore the factors influencing adherence further.  
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 DEFITIONS OF KEY TERMS  
Non-Adherent  
McLean (2003) describes a non-adherent patient as a patient who interrupts treatment for two 
consecutive months or more.   
In this study, a non-adherent patient is a patient who misses two consecutive visits for 
medical appointment at the TB clinic and has not obtained any service from any other facility 
that offers TB services assuming that the patient does not take any TB medication during that 
period or later.   
 Notification rate  
This is defined as the proportion of reported infectious cases such as TB  
Treatment success rate    
This is defined as is the proportion of TB patients who have been successfully cured and 
those who completed treatment.  
Treatment outcomes   
Treatment outcome is described by WHO (2007) as the end product of TB treatment. It 
includes the following: patients who are cured (smear positive patient converted to smear 
negative in the last month of treatment); completed treatment (a patient who has completed 
treatment but who does not meet the criteria to be classified as cured or failure); died (a 
patient who die for any reason during the course of treatment); failed treatment (a patient who 
is sputum smear positive at five months or later at the end of treatment); defaulter; transferred 
out (patient who is transferred to another facility and whose treatment outcome is unknown) 
and successfully treated (these are patients who have been cured and those who completed 
treatment).    
Case notification  
Beaglehole & Bonita (2004: 38), define case notification is as “the reporting system of 
infectious diseases that require prompt action for control.” 
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Treatment Supporter  
A treatment supporter is a trained person, not necessarily a health worker who is chosen and 
trusted by the TB patient to make sure that the patient takes the treatment regularly until 
completion of the treatment duration (WHO, 2010). In this study, a DOT supporter is any 
person chosen by the health worker in consultation with the TB patient.   
 Infection rate  
 Infection rate is defined as “the proportion of the population from which a specific pathogen 
is isolated” (Vaughan & Morrow, 1998:40).  
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1. BACKGROUND TO THE STUDY  
Mycobacterium tuberculosis is the causative agent of Tuberculosis (TB) an infectious 
disease. TB mycobacterium has predilection for the lungs, where it initiates pulmonary TB, 
although the mycobacterium can also infect other body parts and organs, where it may cause 
extra-pulmonary TB. TB disease is air-borne and the infection may spread faster when 
someone is in close proximity with a diseased individual especially in an overcrowded 
environment (Kumar et al, 2007). 
 
According to the World Health Organisation (WHO) (2013), TB remains one of the world’s 
deadliest communicable diseases even though it is avoidable and curable. TB mortality was 
reduced by 45% between 1990 and 2013 and the TB occurrence reduced by 41% during the 
same period (WHO, 2014). However, huge gaps exist in services to manage and treat the 
many TB patients, especially in developing countries, which is a major setback for the control 
of TB spread. In 2013, it was reported by WHO that an estimated 9.0 million people 
developed TB and 1.5 million died from the disease, 360 000 of whom were HIV-positive 
globally. 
 
The five top ranking countries for TB prevalence are India, China, South Africa, Indonesia 
and Pakistan in the order of decreasing magnitude respectively (NDOH, 2013). 
Approximately 1% of the South African population develops TB disease every year (NDOH, 
2011). The provinces affected the most are KwaZulu-Natal, the Western Cape, Eastern Cape 
and Gauteng, which combined have 80% of TB cases in South Africa. Of these, only 54% are 
cured and 13% of patients stop taking treatment (NDOH, 2011). TB is also the most common 
infection for the estimated 5.5 million South Africans living with HIV/AIDS (in a national 
population of approximately 48 million). In addition, the co-infection rate of HIV in South 
Africa is estimated at 73% of all TB cases, a rate the WHO classifies as a serious epidemic 
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(WHO, 2009). South Africa ranks the third highest in the world in terms of TB burden, with 
an incidence that has increased by 400% in the past 15 years (NDOH, 2011). 
 
The first TB treatment medication developed in the 1940s and subsequently, the most 
effective first-line anti-TB drug, rifampicin, became available in the 1960s (WHO, 2014). 
Since then, the WHO has endorsed treatment for cases of drug-susceptible TB as a six-month 
program of four first-line drugs: isoniazid, rifampicin, ethambutol and pyrazinamide. The 
treatment for multidrug-resistant TB (MDR-TB) requires more expensive and more toxic 
drugs as a 20-month treatment regimen with a much lower success rate (WHO, 2014). 
 
1.2. ANTITUBERCULOSIS THERAPY IN SOUTH AFRICA 
The WHO guidelines for TB treatment recommend Directly Observed Treatment, Short-
Course (DOTS) strategy to monitor patient medication adherence (WHO, 2012a; Frieden & 
Sbarbaro, 2007). This strategy includes treating TB using standardized rifampicin-based 
regimens of six-month duration for new TB cases and eight months for retreatment cases. 
The DOTS strategy focuses on five main points of action, these include; government 
commitment to control TB, diagnosis based on sputum-smear microscopy tests done on 
patients who actively report TB symptoms, direct observation short-course chemotherapy 
treatments, a definite supply of drugs, and standardized reporting and recording of cases and 
treatment outcomes. Treatment with properly implemented DOTS has a success rate 
exceeding 95% (WHO, 2012b).   
 
After the end of apartheid rule in 1994, South Africa established the National Tuberculosis 
Programme (NTP). South Africa also developed an integrated National Strategic Plan (NSP) 
for HIV, STIs and TB (2012 - 2016) (NDOH, 2011). In South Africa, once diagnosed with 
TB, patients are provided with anti-TB medication and care free of charge under the DOTS 
programme, in line with the NSP HIV, STIs and TB control programme guidelines (NDOH, 
2011). The targets set in the NSP for TB are to halve new TB cases and mortality by 2016 
and to have no new TB infections, deaths or stigma by 2032. In order to respond to the dual 
epidemics of HIV and TB rationally, South Africa has become the world’s largest provider of 
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preventative isoniazid TB therapy to HIV patients. An estimated 370,000 people living with 
HIV now receive the anti-TB drug to prevent the development of active TB (NDOH, 2011).  
 
The central pillars of TB control in the NTP include diagnosing, treating and preventing TB 
in order to avoid TB deaths and reduce transmission. The South African NTP has 
substantially strengthened the TB control programme since inception in 1994, and the efforts 
of the NTP have contributed to a slow decline in TB case notification rates since 2009 
(Churchyard et al, 2014). The NTP has developed an electronic recording and reporting 
system for drug-susceptible TB (ETR.net) and drug-resistant TB (EDR. net) (Mayosi et al, 
2012). In addition, novel and sustainable solutions, such as the use of mobile phones and 
tablets to collect data in the field and in facilities, are used to strengthen the quality and use of 
data as well as patient management.  
 
South Africa has made notable progress in improving access to TB control facilities, but the 
burden of TB remains enormous. The cure rates remain well below the 85% rate 
recommended by the WHO (WHO, 2012a). The NTP is faced with the challenge of 
integrating TB services into weak primary healthcare systems and the emergence of the HIV 
epidemic, which led to TB case rates multiplying between 1994 and 2012 (Abdool Karim et 
al, 2009).  
 
The growing burden of MDR-TB and the emergence of extensively drug-resistant (XDR) TB 
in 2006 added a further burden to overstretched health services (Abdool Karim et al, 2009). 
However, this situation (i.e. the emergence of MDR-TB and extensively drug-resistant 
(XDR) TB can be reversed through ensuring high, sustained coverage of effective 
interventions for TB and HIV including in children and special populations (miners and 
prisoners). This will substantially reduce the burden of TB and result in the NSP targets being 
met (Abdool Karim et al, 2009).  Finally, new anti-TB drugs, diagnostics and vaccines are 
required to accelerate progress towards TB elimination (WHO, 2012a).   
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1.3. ADHERENCE TO ANTITUBERCULOSIS THERAPY 
Adherence to treatment is defined by WHO as: "the extent to which a person's behaviour- 
taking medication, following a diet, and or executing lifestyle changes, corresponds with 
agreed recommendations from a health care provider" (WHO, 2003:123). Non-adherence to 
medication described as the patient's refusal to adapt to administration of medications as 
prescribed (CDC, 2013a).  Non-adherence to TB treatment medications, identified as the 
leading factor and barrier to TB eradication worldwide (Chaulk, et al, 1995; Daniel, 2006; 
Tumbo and Ogunbanjo, 2011; Ntshanga, Rustomjee and Mabaso, 2009; WHO, 2014; Munro 
et al, 2007). Non-adherence to TB treatment is a major challenge to global TB control 
because it poses a significant threat to both the individual patient and public health and is 
associated with higher transmission rates, morbidity, and costs of TB control programmes 
(Shargie & Lindtjorn, 2007). For the individual, drug resistance and emergence of resistant 
strains would result in an uncertain prognosis and the requirement of more toxic and complex 
drugs (Chesney, 2000). From a public health perspective, the emergence and transmission of 
drug resistant mycobacteria would not only impact negatively on the benefits intended by the 
DOTS programmes but would also result in increasingly more people requiring more 
expensive drugs, thus increasing the costs of the TB treatment programme (Chesney, 2000). 
This public health issue has been a major concern for the impact and feasibility of increasing 
accessibility of TB treatments to more patients in resource limited sub- Saharan Africa 
(Harries et al, 2001; Liechty & Bangsberg, 2003).  
 
A variety of factors may impact on patient medication adherence, and thus efforts to improve 
medication adherence in general are more effective when they address multiple dimensions of 
adherence behaviours than single targeted interventions (Roter, et al., 1998; Charles, 2005). 
Adherence to treatment gives the opportunity to assess factors related to medication intake 
such as characteristics of the regimen, attitudes of the providers; socio-economic, cultural and 
environmental factors (WHO, 2003; Sagbakken, Frich & Bjune, 2008).  
 
Although DOTS has been favoured to influence patient adherence to TB treatment and 
significantly enhance TB treatment outcomes (Daniel, 2006; Tumbo and Ogunbanjo, 2011; 
Ntshanga, Rustomjee, Mabaso, 2009), DOTS coverage and administration have been cited as 
challenges especially in developing nations as there are reports of insufficient or no TB 
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diagnostics to increase case detection, non-participation or non-inclusion of private 
practitioners in DOTS administration, the ever widening funding gap in DOTS-based 
programmes. Also, risk factors for continued TB transmission are not well addressed in most 
developing countries. For example, socio-economic health disparities are still very 
synonymous to health systems on Africa continent; this to a very large extent adds to the ease 
of TB transmission (Chaulk, et al, 1995; Daniel, 2006; Tumbo and Ogunbanjo, 2011; 
Ntshanga, Rustomjee and Mabaso, 2009).  
 
Poor patient adherence to the treatment regimen is a major cause of treatment failure and of 
the emergence of drug-resistant TB. Previous research reported distance to treatment centres, 
gender, patient-caregiver relationship and communication, alcoholism and homelessness as 
the major determinants of adherence to anti-TB treatment (Tanguis et al, 2000; Naing et al, 
2001; O’Boyle et al, 2002). Patient adherence to the standard anti-TB therapy in developing 
countries has been estimated to be as low as 40% (Al-Hajjaj & Al-Khatim, 2000). It is 
therefore important to find better ways to improving patient adherence to TB treatment. The 
present study was undertaken, to determine the extent of adherence and to evaluate the 
factors contributing to adherence in pulmonary TB patients receiving DOTS therapy at a 
Pretoria West hospital.  
 
1.4. DESCRIPTION OF RESEARCH SETTING  
The study location is the Tshwane Metropolitan District, Western Pretoria, Gauteng.  The 
land mass area is approximately 6.17 km² with a population of 11535 (1869.99 per km²) and 
a total of 4084 (662.08 per km²) households (Statistics SA, 2011). This is a low socio-
economic area and 10% of the total population of Pretoria live in this District (Pretoria West 
Palliative Care Forum, undated). The unemployment rate is currently estimated at 39.72%. 
Nine to twenty percent of the households have no income at all. There are 77 squatter camps 
in the district and poverty has increased by above 150% from 1994 to date (Pretoria West 
Palliative Care Forum, undated). Transport in the area is inadequate forcing patients to walk 
to health care facilities (Pretoria West Palliative Care Forum, undated). There are two district 
hospitals and one academic hospital in the district and, all three health facilities administer 
TB DOTS treatment. 
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This study was conducted among smear-positive TB patients diagnosed at the TB clinic of 
one of the district hospitals in Tshwane Metropolitan District. The hospital serves as a 
referral centre for the population of Pretoria West and adjacent informal settlements. The TB 
clinic registers and treats all diagnosed TB patients under the DOTS programme. The 
registers are compiled and reported monthly to the regional TB programme. The TB clinic 
has a record of about 1000 adult patients receiving DOT at the clinic, with an average 
monthly uptake of close to 100 patients. Approximately 98% of these DOT patients were on 
first line regimens. Patients on DOT receive treatment free of charge at the hospital. Patients 
for follow up appointments are seen at the clinic daily and the names of patients due for 
follow up on a particular day obtained from the computer at the clinic. The nurse checks the 
vital parameters like temperature, blood pressure and weight and then directs the patients to 
the doctor who prescribes the drugs and determines the next follow-up appointment date, 
which is usually after one month. Thereafter the patients go to the pharmacy where their 
remaining pills are counted and new ones dispensed. The total number of pills that the patient 
takes home is either recorded in the patients’ health cards or on the pill container labels. 
Since the patients take their health cards home, the records at the hospital only reflect the 
number of pills that are dispensed to the patient and not the total number that the patient takes 
home.      
 
The DOT provider (nurse) co‐ordinates an agreed process of DOT with the patients in this 
clinic. Occasionally, the role of the DOT provider can be extended to include other healthcare 
professionals e.g. pharmacists.   When the role of DOT provider is extended to non‐
healthcare professionals, training and information are provided to such individuals. 
 
The clinic and its staff are committed to implementing and promoting measures to ensure the 
effective and safe management of patients referred for DOT. It is the policy of the clinic that 
healthcare professionals who have undertaken required education and training are facilitated 
to implement and promote the safe and effective management of persons referred for DOT in 
Primary Health Care.   
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In this clinic, all TB patients are the responsibility of the treating physician until their 
treatment has been successfully completed. The referring physician   explains to the patient at 
the outset the rationale and the need for DOT in their specific case, confirms the patient’s 
willingness to comply with DOT and requests DOT by completing the referral form including 
prescription(s).  A copy of the DOT referral form is forwarded to the Tshwane District Health 
services support. The referring physician   also advises when mask‐wearing is necessary, 
inform the DOT provider when there is a change of medication, meet with patients who miss 
DOT doses to discuss problems with adherence, call and chair case‐conferences as needed for 
non‐compliant patients, facilitate hospital admission for patients who are unwilling to comply 
with DOT and for whom self‐medication in the community is deemed inappropriate and also 
assist with the education and training of DOT providers.    
 
In the clinic, there is a senior nurse who occupies the office of the Director of Public Health 
Nursing. She makes sure that appropriate personal protective equipment (PPE) is available as 
required by staff undertaking DOT, ensures robust governance structures in place to monitor 
and audit practice and to ensure patient safety, ensures systems are in place to facilitate 
education and training with regard to the management of DOT and use of PPE and also 
ensures that risk management policies and procedures are in place for reporting all adverse 
events, incidents, near misses and adverse drug events.  
 
The staff supervising DOT administration is accountable for their practice; it is the 
responsibility of each DOT provider to be familiar with the main pharmacological actions, 
the usual dose, storage and stability of medication and frequency, route of administration and 
potential side effects and incompatibilities of the drugs in the management of clients referred 
for DOT. This includes appropriate observation of the patient i.e. observing them take their 
medications, report any difficulties/failures to the treating physician, ensure they take 
appropriate steps to develop and maintain competence with regard to the management of 
clients referred for DOT, adhere to all related policies, procedures, guidelines and protocols 
including risk management structures for DOT and to maintain appropriate documentation 
for DOT administration. 
In the clinic, there is a referral pathway for patients; it involves that the prescribing clinician 
completes a referral form.  The referral form is then forwarded with the prescription to the 
8 
 
relevant Director of Public Health Nursing (DPHN) and cc’d to the Director of Public Health 
and to the patient’s next of kin. The DPHN forwards the referral form and prescription to the 
assistant DPHN who then contacts the Public Health Specialist. The assistant DPHN 
communicates the referral to the DOT provider. Any changes in medication is communicated 
in a timely manner by the prescribing clinician to the patient and to the DPHN.  
 
The DOT provider (nurse or agreed person who is deemed responsible) co‐ordinates an 
agreed process of DOT with the patient.  This involves: ensuring that the medication has been 
obtained by the patient prior to the visit, confirming  the identity of the patient at the time of 
the first visit, observing the client’s condition and recording relevant information, verifying 
that the drugs to be taken are as prescribed.  The DOT provider also observes the patient to 
ensure that the medication has been swallowed, document this in clients’ records which 
include initialling the time and date that medications were taken, report any observed side 
effects of medications as soon as possible to the referring clinician, DPHN and line manager 
as appropriate. The DOT provider for each patient always applies the “five rights” of 
medication administration as follows:   a) The right medication b) The right patient service c) 
The right dosage d) The right form e) The right time.   
 
1.5. PROBLEM STATEMENT 
In Pretoria West, comprehensive TB services are available in 87% of clinics offering the 
DOTS programme and helping to diagnose TB and trace contacts. According to the NDOH 
(2009), the average Pretoria West district DOTS coverage has decreased from 88.8% to 
84.7% in the last few years. The average health district's cure rate is 61%, and its average rate 
of successful treatment of all new smear positive cases has been 66% since 2005. The 
negative trends in TB cure rate are attributable to patients’ adherence responses to prescribed 
TB treatments (NDOH, 2009). WHO (2012a), reports have identified certain factors that 
determine patients’ adherence towards TB prescribed treatments generally, which include: 
TB-related stigma and discrimination in the community, socio-economic status of patients, 
inadequate health system infrastructure, shortage of adequately trained health care workers, 
proximity of patients’ residence to treatment sites, and many more unidentified factors (WHO 
2012a). It is important to explore these factors in other environmental settings (i.e. Pretoria 
West in this case) and verify if the status quo is the same. 
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1.6. RATIONALE OF THE STUDY 
The purpose of the study is to investigate local factors influencing the adherence of smear 
positive TB patients to the DOTS programme in order that recommendations could be offered 
to relevant health authorities in the district to improve adherence and hopefully increase the 
cure rate.  
 
1.7. OUTLINE OF THE STUDY  
CHAPTER 1  
Chapter 1 provides a background to the study, a description of study setting and includes the 
formulation of the problem statement and rationale for the study.   
CHAPTER 2   
This chapter focuses on the review of the relevant literature. The literature review draws on 
issues on the global incidence of TB defaulting, strategies for management of TB, factors that 
contributes to treatment defaulting as well as theories that can be used to explain defaulting. 
CHAPTER 3   
This chapter explains the research methodology namely: the aims and objectives, the research 
design, the study population, sampling, data collection and analysis, rigor of the study, ethics 
considerations as well as limitations of the study.   
CHAPTER 4   
This chapter presents the study results.   
 CHAPTER 5   
This chapter is a discussion of the results of the study in relation to other relevant literature.  
CHAPTER 6   
Conclusion and recommendations are made in this last chapter. 
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CHAPTER TWO 
 
LITERATURE REVIEW 
2. 1. INTRODUCTION 
Although TB can affect anyone, the disease is believed to have poverty as its main risk factor. 
Those living in crowded, unhygienic habitats, those who suffer from malnutrition, or those 
who smoke tobacco; all are at very great risk of developing TB disease (WHO, 2002). In 
addition, those whose immune systems are compromised are at particular risk, which is why 
TB is the number one cause of death among people living with HIV (WHO, 2002). 
In this chapter, the discussion of the literature focuses on TB management and control; 
factors promoting TB adherence; and finally, the barriers to adherence.   
 
2.2. TUBERCULOSIS MANAGEMENT AND CONTROL 
Since 1993, WHO has approved a holistic method of preventing the spread and initiation of 
new TB infections. This is a method that any government at all levels should adopt in 
meeting their responsibilities of managing tuberculosis epidemics within their population 
(Frieden & Sbarbaro, 2007). The method recommended by the WHO (2006a) to be the most 
effective TB intervention is DOTS for restraining the spread of TB in communities as alluded 
to earlier. WHO has reported that more than 30 million patients with TB have been treated 
with its five-element DOTS strategy, resulting in cure rates of more than 80% and default 
rates of 10% (WHO, 2006a).  
The WHO’s declarations on Global Plan to Stop TB emphasises: 
• The need to expand DOTS by standardizing treatment regimen and appropriate TB case 
management  
• Administration of TB treatment in a way that reduces the threat of acquiring TB drug 
resistance mycobacterium  
• Giving all required support to patients in order to facilitate adherence to treatment and 
ultimately enhance the cure rate (Frieden and Sbarbaro, 2007).   
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The WHO launched the DOTS programme as the universally endorsed TB control approach 
in 1994 after recognizing TB as a leading world-wide public health epidemic (WHO, 2006b). 
Most National TB Control Programmes reported breakthroughs and made landslide progress 
in their TB management programmes when the DOTS strategy was employed. Subsequently, 
the strategy was expanded to form the Stop TB strategy, which is a build-up approach that 
seeks to climax the successes of the DOTS strategy (WHO 2006b).  
 
2.2.1. Stop TB strategy  
Most of the successes in TB control globally have been attributed to the DOTS strategy, 
especially in high TB burden countries (WHO 2006b). In order to address the remaining 
challenges, especially in regions where the TB epidemic has worsened (such as sub-Saharan 
Africa and Eastern Europe), a new strategy was developed, namely the Stop TB Strategy 
(WHO 2006b; Dye & Weil 2005). According to WHO (2006c), with DOTS as the central 
component, the Stop TB strategy set out steps which national TB control programmes, their 
partners and stakeholders needed to follow in order to improve their TB control programme. 
It elaborated the DOTS approach with six additional components, as follows: pursue 
rigorously DOTS expansion and delivery enhancement; address TB/HIV co-infection and 
MDR-TB challenges, health systems reinforcement; pro-active approach that include and 
engage all care providers; empower TB patients and enabling and encouraging TB related 
research. These components are expanded on next. 
 
2.2.1.1. Rigorous Pursue of DOTS expansion and enhancement options  
The Stop TB strategy requires all-inclusive and tenacious approaches that support other 
methods aimed at addressing social and environmental factors that contribute to the risk of 
individuals developing TB (WHO 2006b). Furthermore, DOTS strengthening is required in 
the following areas, namely: political commitment with increased and sustained financing; 
case detection through quality assured bacteriology; standardized treatment with supervision 
and support; effective drug supply and management systems; monitoring and evaluation 
systems; and impact assessment (WHO 2006b).  
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2.2.1.2. Address TB/HIV, MDR-TB and other challenges  
The HIV epidemic has worsened the global burden of TB and increased the need to focus 
attention on strengthening the global TB and HIV programmes in order to tackle the two 
public health problems effectively (WHO 2004). TB has become the leading cause of death 
among people living with HIV, while infection with HIV is a large risk factor for latent TB 
infection to convert to active TB disease (WHO 2006c). The international standards for TB 
and HIV as set out by WHO are aimed firstly at decreasing the burden of TB among people 
living with HIV by strengthening intensive TB case finding, provision of Isoniazid preventive 
therapy for TB and HIV co-infected patients and TB infection control in healthcare and 
congregate settings. Secondly, the standards aim at decreasing the burden of HIV among TB 
patients through offering them HIV counselling and testing, HIV prevention and 
Cotrimoxazole prophylaxis, and HIV care and support, including provision of anti-retro virus 
therapy (ART) for eligible patients (WHO 2004). Therefore, collaborative activities between 
the TB and HIV programmes using the above strategies are being implemented as they help 
to control TB among HIV patients (Maher et al, 2002; WHO, 2006b).   
 
The WHO describes multi drug resistance- tuberculosis (MDR-TB) as a threat to global TB 
control, worsened by: inadequate treatment for those suffering from it; increase in MDR-TB 
patients due to misuse of second line anti-TB medicines; and absence of new effective anti-
TB medicines (WHO, 2006c). TB control programmes also need to pay attention to special 
population groups such as prisoners, refugees and other high-risk groups associated with high 
TB transmissions due to overcrowding and poverty (WHO 2006b).  
 
2.2.1.3. Health systems strengthening  
Improving access to quality healthcare services will benefit TB control and therefore TB 
control programmes should actively improve system-wide policy, human resources, 
financing, management, service delivery and information systems (WHO 2006b).  
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2.2.1.4. Engage all care providers (Public-Private Mix)  
Many patients with early symptoms of TB consult private healthcare providers first and many 
such providers diagnose and treat TB (WHO 2006b). The diagnosis of TB needs to be made 
without delay and once diagnosed the correct treatment with adequate dosing needs to be 
instituted with proper follow up of such patients. Thus, engagement of all healthcare 
providers (both private and public) is of paramount importance. Evidence suggests that 
failure to engage all care providers used by those suspected of having TB and TB patients, 
hampers TB case detection, delays diagnosis, leads to incorrect diagnosis as well as 
inappropriate and incomplete treatment, increases drug resistance and places unnecessary 
financial burden on the patients and health systems (Uplekar, et al, 2001) 
 
2.2.1.5. Empower people who have TB 
To achieve greater commitment to fight TB, the Stop TB Strategy embraces the following 
methods: Advocacy, Communication and Social Mobilisation. Advocacy is encouraged to 
influence policy changes and ensure sustained financial and political commitment. 
Facilitation of communication between health care providers, TB patients and their 
communities is important in order to improve knowledge of TB and subsequently compliance 
to treatment. Social mobilization is encouraged to engage the communities, partners and 
stakeholders in the fight against TB (WHO 2006b).  
 
2.2.1.6. Enable and promote TB research  
Conducting locally relevant operational research can identify challenges and practical 
solutions that can be tested in the field before scaling up interventions (WHO 2006b). 
National Tuberculosis Control Programmes can thus develop new and effective strategies for 
TB control. The WHO (2006b) encourages TB programmes to facilitate and actively support 
research to develop new diagnostics, drugs, vaccines and treatments. Qualitative studies must 
be used to ascertain best intervention that would be practicable, maintainable, and that will be 
fully embraced by the patients and the health care services (Lienhardt and Rustomjee, 2006). 
This is believed to be the path toward making TB control more responsive and reflective of 
local health systems.  
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2.3. FACTORS PROMOTING ADHERENCE TO TB TREATMENT  
Several strategies for promoting TB medication adherence have been investigated. These 
include:  
(a) Interventions promoting better health care provider-patient communication about 
adherence. A number of studies have shown the importance of the relationship 
between healthcare workers and the patients as contributing to treatment compliance 
or non-compliance. Bam et al., (2005), in a study conducted in Nepal, found that the 
quality of the health care provider and patient interaction and relationship contributed 
to differences in treatment adherence. Similarly, a South African study (Peltzer, et al., 
2002) established that the quality of health care provider and patient communication 
were associated with TB treatment compliance. 
(b) Developing or improving existing adherence support services that are offered by a 
multidisciplinary team (nurse, physician, pharmacy, patient etc.). A multidisciplinary 
team of providers can provide adherence support that is both comprehensive and 
consistent in its message (Charles, 2005). A team may share office space and 
exchange information several times a day, or they may meet to exchange information 
once a month. A smooth, consistent communication between team members and 
patient is a facilitator to TB medication adherence (Charles, 2005). 
(c) Directly observed therapy (which involves a health care worker, community care 
worker or family member directly monitoring patients swallowing their TB 
medication) (Volmink & Garner, 2007). DOT has been recommended as the standard 
of care for TB disease by the WHO as a keystone of its recommended strategy for 
global control of TB (WHO, 1999). It involves simply supervising the ingestion of 
every dose of treatment. DOT may be the most effective way to ensure completion of 
treatment for TB patients. However, Volmink & Garner (2007) conclude that there 
were not enough evidence to support DOT efficacy.  
(d) Staff understanding of context. Staff members should be educated about relevant   
      cultural beliefs and practices of the communities they serve, and should practice 
      techniques for good communication with patients (Volmink & Garner, 2007). It is  
      crucial to understand the patient population and identify and address socio-cultural  
      differences, as misinterpretation of certain behaviours or intentions can adversely  
      affect the patient-provider relationship. Patients who are uncomfortable or do not  
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      understand providers or program staff may be less likely to initiate or complete  
      treatment. (Volmink & Garner, 2007). 
(e) Education and counselling: It was noted by Gebremariam et al, (2010); WHO (2003); 
Munro et al, (2007); that being knowledgeable about TB disease was also a facilitator 
of TB treatment adherence. Studies have shown that peer counselling was associated 
with higher self-esteem and sense of mastery, characteristics which in turn were 
associated with both the pulmonary (M’Imunya, Kredo & Volmink, 2012) and latent 
TB treatment completion (Morisky et al., 2001).  
(f) Reminder systems and late patient tracers to help patients keep appointments: 
      Reminder systems and late patient tracers are strategies to improve patients' adherence 
      to tuberculosis screening, diagnosis, and treatment as used in some countries (Liu, et 
      al., 2008). Liu and co-authors from this reviewed article affirmed that almost all the  
      reminder trials, except one, show benefits of different types of reminders (visits made 
      to patients, contacts by health workers, letters, telephone calls, e-mails and SMS text  
      messages) compared to no reminder on adherence to tuberculosis clinic appointments,  
      and the authors concluded that the trials show significantly better outcomes among 
      those tuberculosis patients for which late patient tracers and reminders are used (Liu,  
      et al., 2008). 
(g) Incentives and enablers: The use of tangible incentives and enablers has been shown 
      to increase treatment completion (White et al., 2002; Lutge et al., 2012). TB treatment  
      programs regularly provide enablers, i.e. items or services that facilitate clinic  
      attendance. Examples are food, food coupons, bus tokens, childcare facilities,  
      pillboxes, pill splitters and crushers, utensils to administer liquid forms of  
      medications, and calendars to mark off doses taken (Felton, 2004). Incentives are 
      small rewards given to patients to encourage them to take their medications and/or  
      keep their appointments. They may be offered at intervals during the course of  
      treatment or reserved for treatment completion. Incentives can help motivate patients  
      to complete a long treatment regimen, and can serve as rewards for good adherence.  
(h) Social support to assist the patient in being adherent provided (Bosch-Capblanch, et  
      al., 2007; Charles, 2005). The positive impact of social networks and social support 
      on adherence has been demonstrated in studies of health issues including stress 
      reduction, control of alcohol use, smoking cessation, weight loss, blood pressure  
      monitoring, etc. Studies have specifically demonstrated the importance of social  
      support for preventing the progression from latent to active TB disease, improving 
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      adherence to TB treatment, and improving coping and quality of life (Chaisson, et al., 
      2001; El-Sadr, et al., 2001).  
 
In addition, studies have shown that patients who received the support and care of their 
families and community were more likely to adhere to therapy and achieve cure (Macq et al., 
2003; Nyirenda, et al., 2003; Adatu, et al. 2003; Kangangi, et al., 2003). In a study conducted 
in Ethiopia by Gebremariam et al, (2010), it was reported by the health professionals that 
patients who had family support and come to the clinics accompanied by either a family 
member or someone from within the community where they lived, are usually those who 
successfully complete their treatment. The same study also found that participation in TB 
clubs (small support groups of TB patients organised according to location of residence) was 
another facilitator. Observational studies performed in Kenya, Malawi, and Uganda showed 
that the choice of DOT supporter by the patient associated with the decentralization of 
treatment, improved treatment success rates (Nyirenda, et al., 2003; Adatu, et al. 2003; 
Kangangi, et al., 2003). Furthermore, studies in South Africa have reported improvements 
when lay health workers were involved in TB control (Kaplan, et al., 2016; Atkins, et al., 
2010; Clarke, et al., 2005; Lewin, et al., 2005). A study in Nepal, demonstrated that both 
family and community DOT supporters can achieve good treatment outcomes; allowing a 
choice of treatment supporter provided the patients with the capacity to determine the mode 
of supervision that was the most appropriate for their daily life (Newell, et al., 2006). In 
addition, this community-based approach made it possible for community health workers to 
trace default patients and return them to treatment. Thiam et al. (2007), recommend that 
continuous monitoring of this kind of intervention by the district health team is critical for 
continuous positive outcomes. The authors also advise that the monitoring district health 
team should ensure regular supply and safe storage of medication in remote places, and 
regular updates of gathered patients’ data.  
 
TB containment is contingent to proactive treatment strategies to support the process of care 
for patients from detection of disease through the completion of treatment as prescribed 
(Lienhardt & Ogden, 2004). Reports from research studies have shown that interventions 
consisting of a holistic package of continuous efforts targeting all stakeholders in TB 
management and eradication, improved treatment outcomes (Lienhardt, et al., 2003; 
Lienhardt & Ogden, 2004). Well-coordinated public health interventions are mostly designed 
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to focus on several factors that in combination would best address the public health issues. 
This means that interventions developed to facilitate adherence to treatment will usually be 
complex with various resources coming into play in order to mitigate or combat the pressing 
public health menace (Lienhardt, et al., 2003). This will also be true for TB treatment as there 
can be several barriers to TB treatment adherence.  
 
2.4. BARRIERS TO TB TREATMENT ADHERENCE 
There are a number of challenges in fighting TB epidemics including the fact that diagnosis 
can be difficult, particularly in cases of multidrug-resistant forms of the disease (WHO, 
2002). Also, TB treatment is difficult because, full blown TB involves six months of daily 
medication, hence, a major reason for non-compliance with TB treatment programme and a 
platform for the emergence of MDR-TB. MDR-TB requires up to two years of treatment at a 
cost up to 200 times more expensive than standard treatment (WHO, 2002).  
 
Medication non-adherence is a major global major health issue, contributing to unfavourable 
treatment outcomes for a diseased individual (Christensen & Ehlers 2002; Kane et al, 2003). 
Patients may not be able to administer TB medication as prescribed because of many 
overarching circumstances and risk factors. However, these factors are not generic to all 
environments or individuals as they are largely contextual. These likely barriers to TB 
treatment adherence may be categorized as follows: patient-related factors, social factors, 
economic factors and health care and health system related factors (Govender & Mash, 
2009). 
 
2.4.1. Patient related factors: 
Numerous factors have been cited and discussed to be patient related factors that act as 
barriers against DOTS TB treatments by several authors. These factors among many more 
include: Patient cultural beliefs about illness and treatment (Banerji, 1993; Sumartojo, 1993), 
ethnicity, gender and age, patient involvement in drug abuse and mental disorders such as 
depression or alcohol abuse (Hudelson, 1996). More often than not, when patients are 
diagnosed as having TB, communities immediately construct them as social and sexual 
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misfits in the society, which is often followed by exclusion from social interactions and 
relationships (Glynn et al., 2001). Where care is given in homes, a patient may experience 
feelings of intense loneliness and abandonment (Glynn et al., 2001).   
 
A study by Date and Okita (2005) demonstrated that the educational levels of TB patients in 
Yemen were significant predictors of treatment compliance. Similarly, Belo, Luiz, Teixeira, 
Hanson and Trajman (2011) conducted a prospective study in Brazil and found that 
educational background is among the most important determinants of socio-economic status 
and that all deaths due to TB occurred in the group with a lower educational level. It can 
therefore be deduced based on these cited studies that educational level is a cogent factor in 
treatment adherence; that is, high education status is a facilitator to treatment adherence, 
while limited education status of the patients is a barrier to treatment adherence.  
 
According to WHO (1999), some of the personal barriers postulated to be contributing to 
poor TB treatment compliance are: alcohol, substance abuse, depression and other psychiatric 
illnesses. Similarly, in a systematic review by Munro et al. (2007), depression, alcohol and 
substance abuse have been identified as factors that negatively influence compliance of 
patient on medications. The implications of patients taking alcohol while on treatment are 
twofold. Firstly, patients may forget to take their medicines when drunk, and secondly there 
may be more side effects to TB medicines, particularly when patients are taking other 
medicines, which may result in their being non-compliant (Munro et al., 2007). Smoking may 
also result in delayed healing from treatment, in turn giving the patients the false impression 
that the TB medicines are not working and cause them not to be compliant (Munro et al., 
2007).  
 
The personal beliefs of patients may constitute an important group of factors affecting 
adherence even in the presence of adequate access to treatment. In a qualitative review of 
literature from 1970 to 2005 comprising of more than 102 articles on factors affecting 
therapeutic compliance from the patients’ perspective, the authors found that patients’ 
misconceptions or erroneous beliefs contributed to non-adherence (Jin et al., 2008). The 
review showed that patients’ fears about treatment, their belief that the disease could not be 
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controlled and their religious beliefs all contributed to the likelihood of non-adherence to 
therapy (Jin et al., 2008). Misconceptions can influence care-seeking behaviour, implying 
that if a TB patient misconceived the cause of the sickness, then care-seeking behaviour 
could also be faulty. The findings of a qualitative study conducted in Kenya on care seeking 
and attitude towards TB compliance, showed that some participants thought that 
environmental factors such as inhaling smoke and hot air from burning charcoal or sharing a 
house with domestic animals were the cause of their TB symptoms and therefore, if they can 
avoid these misconceived causes of their sickness, they will be healed and there will be no 
need for comprehensive TB treatments programme. Other patients thought that TB was 
contracted through alcohol consumption, water or sharing utensils (Ayisi et al., 2011). 
Similarly, in Ethiopia, some participants thought that ‘evil spirits’, sexual intercourse and ‘the 
cold’ were causes of TB (Gebremariam, Bjune and Frich, 2011). These misconceived causes 
of TB have contributed to TB patients’ non-adherence to recommended TB treatments.  
 
2.4.2. Social influences 
Psychosocial issues like stigma and discrimination of TB patients have been cited as barriers 
in fighting TB epidemics; these psychosocial factors leave sick people too fearful to seek out 
treatment promptly. Several studies show that actual experiences and anticipations of stigma 
resulted in many patients hiding their diagnosis of TB or only disclosing it to selected people, 
mostly close families, which can impact negatively on adherence to TB treatment 
(Gebremariam, Bjune, & Frich; 2011, Courtwright &, Turner, 2010, Deribew et al, 2010). In 
a qualitative study to explore lay beliefs about TB and TB/HIV co-infection in Addis Ababa, 
Ethiopia, many TB patients believed that they were victims of stigma and discrimination 
because of their TB status (Gebremariam, Bjune, & Frich; 2011). Some believed that their 
stigma was mainly due to the fact that people associated TB with HIV. Many had seen other 
TB patients suffering from stigma and discrimination in their communities, and feared that 
the same might happen to them.  
 
2.4.3. Economic factors:  
Economic factors cover patients’ employment status, socio-economic status, and cost of 
transport to clinic while undertaking TB treatment. Several studies on adherence to 
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medications especially DOTS have shown some associations between economic factors and 
adherence. According to Lamsal et al., (2009), poverty and TB are closely connected. They 
claim that the poor may have less flexibility regarding work and clinic attendance and less 
ability to pay for medications and transport. Nurses who took part in a phenomenological 
study by Sissolak, Marais & Mehtar (2011) conducted in Cape Town, South Africa, reported 
that their TB patients came from poor socio-economic conditions and lived far from the 
hospital. Some of them did not have decent housing because they lived in shacks, their 
nutritional status was poor and they were unemployed and had no money to travel to the 
hospital. The study found that all these factors contributed to low adherence level to TB 
treatment (Sissolak, Marais & Mehtar, 2011). 
 
Studies in Nepal (Bam & Gunneberg 2006), Uzbekhistan (Hasker et al, 2008), Malaysia 
(O‟Boyle, et al, 2002), Swaziland (Pushpananthan, Walley & Wright 2000:), and Zambia 
(Needham & Godfrey Faussett 1998) indicated that cost of transport accounts for non-
compliance to TB treatment. In the Malaysian study, cost and time of travelling to the 
treatment centre were major contributory factors associated with compliance to treatment, as 
non-compliant patients paid significantly more for transport than those compliant (O‟Boyle 
et al, 2002). A prospective cohort study in Southern Ethiopia to determine factors predicting 
treatment adherence among smear positive pulmonary tuberculosis patients found that among 
404 TB patients on treatment, 20% defaulted treatment. Ninety-one percent of treatment 
interruptions occurred in the continuation phase, when they had higher cost of transport to a 
treatment facility (Shargie et al, 2007). One of the explanations for this finding might be that 
during this phase most of the symptoms disappear and patients may erroneously believe they 
are cured. This may encourage them to become reluctant to bear the extra burden of the cost 
of travel, time, and drug side effects (Shargie et al, 2007). 
 
2.4.4. Health care and health system related factors 
While the use of multidisciplinary services improves adherence, it has been recognized that a 
strengthened referral system, simple regimen (number of pills, and frequency of dosing) all 
improve adherence (Jin et al., (2008). One of the factors that may affect adherence has been 
found to be physician-patient relationship (Fochsen, et al., 2009; Munro et al., 2007; Jin et al., 
2008). Prior research has suggested that collaborative communication between physician and 
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patient is associated with better adherence (Heisler et al, 2007; Naik et al, 2008; Schoenthaler 
et al, 2012). In a study conducted in northern California, USA, among 9,377 patients taking 
medications to lower their blood sugar, blood pressure or cholesterol, it was observed that 
30% of participants were not necessarily taking their medications the way their doctors 
thought they were, due to lack of proper communications. On the other hand, in the same 
study, the rates for non-adherence were 4 - 6% lower for patients who felt their doctors 
listened to them, involved them in decisions and gained their trust (Ratanawongsa et al, 
2013). The study suggests preparing doctors to be better communicators may help improve 
medication adherence and ultimately health outcomes (Ratanawongsa, et al 2013). In another 
study conducted in Auckland, New Zealand on physician-patient relationship and medication 
compliance by Kerse et al (2004), of almost 400 participants, it was concluded that a greater 
order of physician-patient concordance was associated with increased medication 
compliance. The authors suggested that “an emphasis on understanding and facilitating 
agreement between physician and patient may benefit outcomes in treatment/medication 
adherence” (Kerse et al, 2004:455). 
 
Complex treatment has been cited as a factor that acts as a barrier to patients’ compliance. 
Pill burden, pill fatigue, side effects and complexities and timing of dosing have all been 
cited as factors influencing adherence. For example, in a reviewed article of barriers and 
facilitators to anti-TB medication by Paliwal (2010), the study identified duration on 
medications and complexity of treatment as some of the factors that influenced adherence. It 
has been reported that adherence to TB treatment has direct association with the number of 
drugs prescribed in a treatment (Horne & Weinman 1999; Patal & Taylor 2002; Grant et al, 
2003; Iihara et al, 2004), and correlated to the dosing times per day of all prescribed 
medications (Kass et al, 1986; Cockburn et al, 1987; Cramer et al, 1989; Eisen et al, 1990; 
Cramer 1998; Sung et al, 1998; Claxton et al, 2001; Iskedjian et al, 2002). It infers that the 
rate of compliance decreased as the number of daily doses increased; this is revealed in a 
compliance study that assessed pill counts and self-reports, where it was revealed that non-
compliance increased as dosing times increased: 20% for once daily; 30% for twice daily; 
60% for three times a day; and 70% for four times daily (Cramer et al, 1989). It has also been 
reported that, three times daily therapy was the frequent factor for poor adherence, and that 
the best improvement in adherence comes with the reduction of dosing frequency from three 
to two times a day (Jin et al, 2008). Similarly, a meta-analysis found that there was a 
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significant difference in compliance rate between patients taking antihypertensive medication 
once daily and twice daily (92.1% and 88.9%, respectively) (Iskedjian et al, 2002). Thus, 
simplifying the medication dosing frequency could improve compliance significantly.  
 
DOTS Treatment observers are key to the success of tackling problems of acute non-
adherence to treatment (Paliwal, 2010). According to Paliwal (2010), there are no universal 
criteria used in assigning treatment observer but in the choice of a treatment observer for a 
patient, the priority factor should be accountability of the observer to the health system. An 
observer could be members of the civil society, health care facility staff, social workers and 
members of non-governmental organizations, religious and ethnic leaders (Paliwal, 2010).  In 
commenting on the importance of direct observation, Frieden & Sbarbaro (2007:409) 
concluded that “Perhaps what is most important is to ensure that the approach is patient-
centered, with rigorous monitoring of and accountability for ensuring cure, and rapid 
intervention to increase cure rates if they are less than 85%”.    
  
A study evaluating DOT in South Africa demonstrated that the facilities with high DOT 
coverage had significantly better adherence rates than those with low DOT coverage 
(p=0.045) (Ntshanga, Rustomjee & Mabaso, 2009). In 2008–2009, the South African NTP 
implemented a national pilot project, the TB Tracer Project, to decrease default rates and 
improve patient outcomes, by constituting teams dedicated to following up TB patients 
(Podewils, et al, 2012). In an evaluation study based on data from routine national TB 
surveillance, it was revealed that sub-districts that participated in the TB Tracer Project had 
more patients who adhered to TB treatment and better treatment outcomes over the project 
period, in comparison to sub-districts that were not part of the tracer project (Podewils, et al, 
2012; Bronner et al, 2012). Invariably, following up on patients with adequate traceability 
plans is a major player and inevitable facilitator to treatment adherence. 
 
A Nigerian study reported that implementing DOTS in hospitals led to a significant increase 
in the number of patients completing treatment and a significant reduction in mortality among 
TB patients (Daniel, 2006), which meant that DOTS can help to ensure that patients adhere to 
and complete TB treatment regimens.  
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2.5. SUMMARY   
Adherence has been identified as a key element in reducing the likelihood of the emergence 
of drug resistant TB mycobacteria. Hence, the global efforts towards increasing access to TB 
treatments through DOTS, especially in resource-limited settings, should match availability 
of TB medications with successful treatment outcomes to avoid the emergence of drug 
resistant strains. Though earlier apprehension of low levels of DOT adherence in resource-
limited settings has been proven unfounded, adherence may still be a concern in such 
environments. Identifying contextual factors that affect adherence to DOTS is an important 
process in designing interventions aimed at sustaining optimal adherence levels.  
   
Different context and people have their own peculiar characteristics; these factors are 
fundamental and germane to successful implementations of DOTS to TB patients in any 
environment or setting. Addressing psychosocial, demographic and health system factors that 
affect adherence are the hallmark of adherence enhancement (Laurenzi, Ginsberg & 
Spigelman, 2007). Improving adherence should be proactively done through identification of 
possible barriers during counselling and planning how to appropriately address them before 
the first drug prescription is made. Such strategies include those that encourage close patient-
provider contact, social support and education and anticipating problems that may promote 
non-adherence.  
 
The next chapter outlines the specific objectives of the present study and the methodology 
used in the study to achieve these objectives.     
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CHAPTER 3 
 
METHODOLOGY 
In this chapter the research methodology will be discussed in detail, covering aim of the 
study, study objectives, research design, population and sample, the research instrument, 
research assistants, data collection and analysis, ethics and reliability and validity. 
 
3.1. AIM OF THE STUDY 
The aim of this study was to assess the determinants of adherence to DOTS therapy amongst 
TB patients who commenced TB treatment at the TB clinic of a district hospital in Pretoria. 
 
3.2. OBJECTIVES OF THE STUDY   
The specific objectives of this study were: 
I. To measure the level of adherence to DOTS in patients attending the TB Clinic in a 
Pretoria district Hospital. 
II. To assess the associations of socio-demographic, cultural, religious and health systems 
factors with TB patients’ level of adherence to DOTS at the TB Clinic. 
 
3.3. STUDY DESIGN 
A quantitative descriptive and analytical, cross-sectional study design was used for this study. 
According to Burns and Grove (2005), cross-sectional study designs examine participants 
simultaneously, irrespective of their stage of development but with an aim to describe 
differences in phenomena across stages. Data are collected at a point in time but with 
different study participants, as opposed to different points in time for the same participant 
(Brink 2007). Thus, the study is conducted in the present to determine what already exists; 
also, exposure and disease status are measured simultaneously (Joubert et al 2008). Cross 
sectional studies are relatively easy and not very expensive to conduct, since they involve 
data collection at one point in time only (Polit et al 2001). This study involved collection of 
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data over a 3-month period of time (April – June 2014) and was thus very economical. Also, 
a cross sectional study is useful for evaluating the relationship between exposures and 
outcomes (Gordis, 2004). In this study, associations were tested for various exposures, such 
as sex, educational level, distance from clinic, socio-economic status, alcohol use, DOT 
status and health system factors with the two outcomes (adherence and non-adherence).  
 
A cross sectional study is an important step in first assessing the possibility of a relationship 
between an exposure and a disease before more complicated or expensive studies are 
undertaken, such as case-control and cohort studies (Gordis 2004; Stommel & Wills 2004). It 
is useful in identifying the factors associated with TB DOTS adherence or otherwise in a 
Pretoria West district clinic, which could pave the way for other studies that could identify 
the factors of treatment non-adherence more broadly.  
 
However, the main disadvantage of cross-sectional studies is their failure to establish 
causation and the temporal relationship between exposure and disease or outcome as the two 
are measured simultaneously (Gordis 2004; Stommel & Wills 2004; Polit et al., 2001; Joubert 
et al., 2008). However, this was not a major limitation as this study aimed to identify 
associated factors and not necessarily the causes.  
 
3.4. STUDY POPULATION  
The study population constituted patients aged 18 years and above who registered for the 
DOTS programme at the TB clinic of a district hospital in Pretoria. Specific inclusion criteria 
were: 
 Patients on first line regimens of DOTS for TB;  
 Patients who had started on DOTS at the Hospital during the 6-month period prior (6 
months before November 2014) to the commencement of the study.  
 
The rationale for selecting the study population is that: 
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i. Adherence measures in patients under 18 years of age, may more likely have different 
factors to adherence in adults such as factors related to supervision of medication by 
caregivers’ rather than particular choices made by the patients themselves.  
ii. Patients visiting the hospital for a period of six months at least in order to gain the sample 
size required.  
Only those patients who fitted the inclusion criteria and who were willing to participate were 
included in the study.  
 
3.5. SAMPLE SIZE 
The sample size was determined using EPI Info version 7 (CDC, 2013). The study population 
was estimated to be 1,000 (verbal communication with the TB clinic nurse) and the expected 
prevalence of patients achieving optimal adherence (taking > 95% of medication) was 
between 84% as the best acceptable rate and worst acceptable estimate was 80%. The 
estimates were based on two provider estimates using pill count records at the pharmacy 
(adherence pattern estimates from clinic pharmacy record for previous TB patients on 
DOTS). Using 95% confidence levels, the required sample size was determined to be 234. 
 
An all-inclusive sampling method was applied in this study i.e. all the patients (215 
individuals) on DOTS who fitted the inclusion criteria at the TB clinic for the sampling 
period (3 months) were approached for participation in the study. Their names were obtained 
from the TB clinic registers with the help of the nurses working in the clinic. Those who 
fitted the inclusion criteria but were not willing to participate in the study (135 individuals) 
were excluded, hence the small sample size of 80 individuals who consented to participate in 
the study.   
 
 
3. 6. DATA COLLECTION TOOLS 
In the current study, data was collected from the TB patients using a structured questionnaire 
at one point in time for each of the patients. While the data collection was at different times 
for the different patients, it was collected once for each of them. The data collection tool (see 
Appendix 1) was a structured questionnaire in English. The questionnaire was adapted from 
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those used in other adherence studies from developing countries (Kgatlwane et al., 2006; 
Irunde et al., 2005).  The research assistants asked the questions verbally in Tshwana 
language and filled in the answers in English in the questionnaire. The research assistants 
were fluent in both English and the local language. The questionnaire was divided into three 
parts: 
 The first part collected socio- demographic data; 
 The second part collected data related to treatment, and; 
 The third part collected data related to the adherence measurement tools.  
 
Socio-demographic data 
The socio-demographic variables included age, sex, marital status, level of education, place 
of residence and the nearest health facility.  
 
Treatment data 
Treatment data included duration on treatment, experience with side effects and knowledge 
of consequences of failing to take medication as prescribed. Data such as duration on 
treatment were collected as month while all the other questions were in a multiple-choice 
format. The question on treatment regimens were verified by comparing information from the 
patients’ pill containers with the patients’ health cards to ensure accuracy. 
 
Adherence measurement tools 
The third part of the questionnaire collected adherence data using three different measures: a 
30-day self-report using a visual analogue scale, 2-day recall using a sun and moon chart and 
a pill count. The 30-day visual analogue scale required participants to pour beads from one 
container representing the pills they were supposed to have taken in a period of 30 days, into 
another container representing the pills actually taken in the same period. The pills left in the 
first container therefore represent the pills missed and adherence was measured using a line 
marked 1-10 on the first container. This was done for each drug in the regimen.  
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The visual analogue scales has been extensively used for assessment in a number of health 
domains and has therefore accumulated substantial support as a valid and efficient tool for 
use in assessment of medication adherence (Giordano et al., 2004; Amico et al., 2006; 
Bangsberg et al., 2000; Oyugi et al., 2004). Studies using pill count, visual analogue scales 
and questionnaires in monitoring adherence to treatment medications have reported good 
concurrence between pill count and visual analogue scales (Nackers et al., 2012; Amico et al., 
2006; Bangsberg et al., 2000; Oyugi et al., 2004). Walsh, Mandalia and Gazzard (2002), also 
included visual analogue scales as an adherence assessment in the Medication Self-report 
Inventory, and when used to assess adherence to a single antiretroviral medication, visual 
analogue scales scores correlated significantly with Medication Events Monitoring data, pill 
counts, and viral load data. In this study, a 30-day self-report using a visual analogue scale 
was adopted to monitor adherence to TB medication based on the above cited published 
works. 
 
The pill count was obtained by determining the number of pills returned, the number of pills 
dispensed in the previous refill and the number supposed to have been taken in a given 
period. This information was obtained from the pill containers and the patients’ cards. 
Adherence was then calculated as the number of pills supposed to have been taken minus the 
number of pills missed in a given period as the numerator and the total number of pills 
supposed to have been taken in the same period as the denominator. This was calculated for 
each drug in the regimen and the average computed. Adherence rates that were over 100% 
using this adherence measure were recorded as 100%. 
 
The two -day recall used a sun and moon chart that also indicated time in one-hour intervals. 
The participants were requested to state the time when the dose of each drug in the regimen 
was taken starting from the previous day to two days prior. Adherence was then calculated as 
a percentage of the interval between the doses in relation to the interval required. 
 
3.7. DATA COLLECTION PROCEDURE 
Two research assistants, (2 trainee nurses) conducted the interviews with patients on DOT at 
the hospital over a three-month period (April – June) from the time permission was granted 
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for the research. The two research assistants obtained the list of names drafted from the 
register on the days the participants had appointments at the clinic to identify the selected 
patients who were interviewed immediately after their appointments. The first assistant 
administered the first and second parts of the questionnaire and the second assistant the third 
part. The administration of the questionnaire done by the first research assistant was preceded 
by providing participants with an information sheet (see Appendix 3 and 4) and an informed 
consent form in their preferred language (see Appendix 2 and 5) accompanied by a verbal 
explanation of the purpose of the study and requesting their voluntary participation. Only 
after the participants had signed the consent form, did the interviews commence with 
questions being asked orally. The completed questionnaire was then coded using the patients’ 
DOTS number before being passed on to the second research assistant. 
 
The second assistant checked the questionnaire for completeness of information collected by 
the first assistant and then confirmed that the DOTS number on the questionnaire corresponds 
to the DOTS number on the patients’ health card and that on the patient’s pill containers. 
Next, the second assistant also completed details of the patient’s treatment regimen on the 
questionnaire by confirming that the pills prescribed on the patients’ file were the same as the 
pills or containers presented by the patient. This research assistant then proceeded with the 30 
day and 2-day adherence self-report using the pill containers to ensure that adherence was 
reported for each drug in the regimen. This assistant also obtained pill count data from the 
patients’ cards, pill containers and actual counting of the returned pills. The pill was counted 
on the patient’s clinic appointment day for those pills taken/not taken between the last 
appointment day and the present day; which is approximately 30 days. 
 
3.8. DATA MANAGEMENT AND ANALYSIS  
All answers to questions requiring computing were entered on the questionnaire and double-
checked by the researcher for completeness and accuracy at the end of each day. The 
researcher developed a written codebook detailing standard procedures and this was used to 
code the questionnaires, which were then double entered into Excel files by the two research 
assistants. The two files were then compared and anomalies or missing data between the two 
entries were checked using the questionnaires. The entered data were scrutinized for invalid 
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values and impermissible combinations and counterchecked with the questionnaires. These 
data were then exported into EPI Info version 7 (CDC, 2013). 
 
Adherence was analysed both as a categorical variable which was expressed as high (> 95%), 
moderate (85% - 94%) and low adherence (< 85%) level; and as a dichotomous variable as 
optimal (> 95%) and sub optimal levels (95%). Bivariate analysis was done to test the 
significance of associations between outcome variables (2-day recall; 30-day recall; pill 
count; and composite measure) and predictor variables (age; sex; marital status; education 
level; disclosed status; regimens; medication knowledge; and reported side effects) 
separately. The p-value cut-off for significance was P ≤ 0.05. The prevalence ratio and 95% 
confidence interval was used as the measure of effect of outcome and predictor variables on 
adherence.  
 
3.9. GENERALIZABILITY 
The small sample size of 80 participants in the study limits the generalizability of the results 
The results obtained have to be viewed with caution, as external validity might have been 
compromised by using such a small sample, rather than studying the entire population or a 
truly random sample.  
 
3.10. VALIDITY AND RELIABILITY  
Reliability and validity of a measuring instrument are very important (De Vos et al., 2007). 
To obtain valid and reliable data from the measuring instrument it is important to ensure that 
before administering the instrument it can be replicated and provide accurate information for 
the researcher to draw acceptable conclusions (Stommel & Wills 2004).  Reliability arises 
from the stability and consistency of the measurement and provides an indication of the 
random error in the measurement (Burns & Grove 2005). In this study, measurement bias was 
reduced by the use of multiple adherence measures to ensure accuracy of adherence 
estimates, as strengths of one method compensate for the weaknesses of another. The 
measuring instruments in this study were not piloted due to lack of finance and time 
resources and most specifically because it was difficult to recruit willing participants.  
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However, the adherence measuring instruments in this study were adopted from other studies 
where they had been tested and proven as reported by Burns & Grove (2005) and De Vos et 
al., (2007). In order to ensure reliability of the measuring instrument, closed-ended questions 
were used in this study; this ensures that the participants give unbiased responses.  
 
Validity is a measure of the truth or accuracy of a claim (Burns & Grove, 2005) and, 
according to Babbie (2004); it refers to how far a data collection instrument actually 
measures what it is supposed to measure. Validity has two aspects: firstly, that the instrument 
does in fact measure the concept it is intended to measure and secondly that it is measured 
accurately. Double-checking of recorded information and data in the questionnaire was 
carried out by the research assistants and confirmed by the chief researcher in order to ensure 
accuracy and completeness. 
 
 Social desirability is a perceptive bias in which participants answer to questioning in ways 
that make them seem more favourable or appealing to others. Participants can over-report 
their positive behaviours and under-report negative behaviours and qualities. Social 
desirability which is usually associated with self-reporting was minimized in this study by 
phrasing the adherence questions in a non-threatening manner and by the use of research 
assistants (who are clinic nurses and who are privy to the participants’ attitudes to treatment 
and clinical history and therefore knew how to approach the participants and how to ask the 
questions) to administer the questionnaire to the participants, rather than the chief researcher. 
The importance of truthful information in relation to the purpose of the study was explained 
to the participants, which hopefully reduced social desirability. Social desirability based on 
the use of clinic nurses were minimized by encouraging the participants to complete the 
questionnaires by themselves in the local language.  
 
3.11. ETHICS  
Verbal and written explanations about the study were given to the patients in their language 
of choice. They were also told that they could withdraw from the study at any time and that 
their withdrawal from the study would not compromise their treatment in any way. They 
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were also informed that their identities would be kept confidential. Verbal or written consent 
was obtained from the participants prior to participation. Approval for the study was obtained 
from the Senate Research Committee of the University of the Western Cape. Permission was 
also obtained from the District Health Manager and the facility manager of the research site. 
Permission to examine hospital records was secured from the District Hospital authorities. 
Careful measures were taken to treat the patients’ medical records with confidentiality and 
this was conveyed to the participants. All identification data were stored in the computer 
database that was accessible only to the researcher and was password protected and was only 
shared with the supervisors.  
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CHAPTER 4 
 
RESULTS 
In this chapter, the research findings are presented and include socio-demographic information; 
clinical characteristics of participants; optimal adherence characteristics of participants; reasons for 
missing doses; facilitators for taking doses correctly; reasons for missing DOTS clinic appointments; 
and lastly factors affecting adherence to DOTS. 
 
4.1. SAMPLE REALISATION 
Sample size for this study calculated to be 234; however, patients who were willing to 
participate in the study during data collection were below the calculated sample size.  
 
4.2. SOCIO-DEMOGRAPHIC CHARACTERISTICS OF PARTICIPANTS 
A total of 80 DOT patients participated in the study. The majority of the participants were 
male (76.25 %, n=61), while 23.75% (19) were female; this is representative of the clinic 
clients (e.g. clinic data: male = 162; female = 54). Table 4.1 summarises the socio-
demographic characteristics of the participants. The mean age of the participants was 36 
years; 23 (28.75%) of the participants were in the 20-29-year age group; 22 (27.5%) of the 
participants were in the 30-39-year age group; 33 (41.25%) of the participants were in the 40-
49 age group; 2 (2.5%) of the participants were in the 50-59 age group; and there were no 
representative participants from age group 60+ years in this study.  
 
The marital status data of the participants revealed that 30 (37.5%) of the participants were 
married or cohabiting; 23 (28.8%) were divorced; 17 (21.3%) were single and 10 (12.5%) of 
the study participants were widowed. Slightly more than half of the participants (41[51.3%]) 
had attained primary education level status, while, 30 (37.5%) of the participants had 
secondary education level status.  A total of 9 (11.3%) of the participants had no formal 
education, while none of the participants had achieved tertiary education status.  
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Table 4.1: Socio-demographic characteristics of TB Patients on DOTS (N=80) 
Characteristics n (%) 
GENDER Male 61 (76.25) 
Female 19 (23.75) 
AGE (in years) 
 
 
 
 
20-29 23 (28.75) 
30-39 22 (27.5) 
40-49 33 (41.25) 
50-59 2 (2.5) 
60+ 0 (0) 
MARITAL STATUS 
 
 
Married /cohabiting 30 (37.5) 
Divorced 23 (28.8) 
Single 17 (21.3) 
Widowed 10 (12.5) 
EDUCATION LEVEL 
 
 
No Schooling  9 (11.3) 
Primary 41 (51.3) 
Secondary  30 (37.5) 
Tertiary                    0 (0) 
DISTANCE TRAVELLED 1 - 5 Kilometres 31 (39) 
6 - 10 Kilometres 16 (19) 
11 - 15 Kilometres 9 (11) 
16 - 20 Kilometres 10 (13) 
21 - 25 Kilometres 13 (16) 
>25 Kilometres 1 (2) 
 
Table 4.1 also shows the distances travelled by the participants to the hospital. Thirty-nine 
percent of participants travelled up to five kilometres from their homes to the hospital; 43% 
and 16 % of the participants travelled between 6-20 kilometres and 21-25 kilometres 
respectively, to get to the hospital; while just 2% reported that they had to travel over 25 
kilometres. The average distance travelled by all of the participants to arrive at the hospital 
was approximately 11 kilometres.  
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4.3. CLINICAL CHARACTERISTICS OF PARTICIPANTS 
Most of the participants (88.8%, n=71) were on the first two-month intensive phase treatment 
combinations that contained Isoniazid + Rifampicin + Pyrazinamide + Ethambutol, while the 
remainder of the participants (11.2%: n=9) were on the continuation phase of the DOTS 
treatment.  
 
Table 4.2 shows the length of time participants had been on DOTS programme. The mean 
duration those participants had been on DOTS treatment was approximately 17 weeks while 
the median duration on DOTS treatments was around 13 weeks. Approximately 43.8% 
(n=35) of the participants had been on DOTS for at least16 weeks.  
 
 Table 4.2: Clinical characteristics of participants (N=80). 
 
DOTS REGIMEN 
Dosing Duration 
(Month) 
    No. (%) 
 
Isoniazid + Rifampicin + Pyrazinamide + Ethambutol   
 
2 
 
   71 (88.8) 
Rifampicin + Isoniazid 
 
4    9 (11.2) 
Duration on DOTS Treatment (Weeks) No. of DOTS Users (%) 
 
≤ 12 
 
                   10 (12.5) 
13 - 16 25 (31.25) 
17 - 20 31 (38.75) 
21- 24                    12 (15) 
> 24 
 
                     2 (2.5) 
Adherence Measure % Mean Adherence (SD) 
 
30-day recall visual analogue 
 
92.8 (5.73) 
2-day recall sun and moon chart 95.6 (3.10) 
Pharmacy refill record (pill count) 93.4 (5.16) 
Composite adherence of the 3 measures  94.0 (4.66) 
 
36 
 
The mean adherence rates obtained using 30-day self-report (visual analogue), 2-day self-
recall (sun and moon chart) and pill count were 92.8%, 95.6% and 93.4%, respectively. The 
mean composite adherence of the three measures gave an adherence rate of 94% (Table 4. 2). 
 
Most (80%; n=64) of the participants reported having experienced some side effects with 
anti-TB medication, while all of the participants reported having disclosed their TB status to 
somebody else apart from the mandatory treatment supporter.     
 
When asked about the consequences of failing to take anti-TB medication as prescribed, 80% 
(n = 64) of the participants answered that they understand that they would remain sick while 
20% (n= 16) of the participants answered that the mycobacterium will develop resistance in 
their body and the drugs will not work later when they resume the treatment again. All of the 
participants answered that if they stopped taking their medication or stopped taking it 
correctly, their health will deteriorate and therefore become sicker. Any of the three answers 
was considered as DOTS knowledge.   
 
4.4. OPTIMAL ADHERENCE CHARACTERISTICS OF PARTICIPANTS (N = 80)  
The proportion of DOTS patients who achieved optimal adherence levels (95% and above) 
was 60%, 91% and 73% as measured by 30-day visual analogue, 2-day recall and pill count, 
respectively; the differences in optimal adherence values from the 3 methods used could 
mean effectiveness and sensitivities of one measurement technique over the other. Using the 
mean composite of the three adherence measures, it was found that 75% of the DOTS users 
had achieved optimal adherence levels (Table 4.3).   
 
4.5. REASONS FOR MISSING DOSES   
All of the participants reported that they had missed doses of their medications at one time or 
the other. Reasons given by the participants for missing doses varied from being away from 
pills (9%), reacted to medications (21%), forgetfulness (40%), alcohol use (10%) and lack of 
food (20%) (Table 4.4).  
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Table 4.3: Measure of adherence by Categories 
 
 
ADHERENCE 
MEASURE 
CATEGORY OF ADHERENCE 
 
High                              
( 95-100) 
Medium                      
(85-< 95) 
Low                                 
( < 85) 
 
30 day visual 
analogue   (N = 80) 
 
48 (60%)                
(95% CI: 49.3-69.7%) 
 
20 (25%)                    
(95% CI: 15.5-33.5%) 
 
12 (15%)                 
(95% CI: 8.1-21.9%) 
 
2 day sun & moon 
chart (N = 80) 
72 (91%)                          
(95% CI: 84.5-95.3%) 
5 (6%)                                
(95% CI: 2.5- 11.5%) 
3 (3%)                            
(95% CI: 1.4- 8.5%) 
 
Pharmacy Pill count         
(N = 80) 
58 (73%)                          
95% CI: 64.5-82.3 %) 
13(14%)                           
(95% CI: 9.5-20.9 %) 
9(12%)                        
(95%CI: 6.3-19.5%) 
 
Composite adherence 
of  the 3 measures              
(N = 80) 
60 (75%)                     
(95% CI: 63.5-78.4 %) 
18 (22%)                      
(95% CI: 18.9-32.2%) 
2 (3%)                                     
(95% CI: 1.1-7.2%) 
 
 
Table 4.4: Reasons for missing doses (N = 80)  
Cited Reasons Number of participants (%) 
Away from pills 7( 9) 
Reacted to medication  17 (21) 
Forgot 32 (40) 
Alcohol use 8 (10) 
Lack of food 16 (20) 
 
4.6.   FACILITATORS FOR TAKING DOSES CORRECTLY  
 Seventy-two percent (n = 58) of the participants cited counselling and having treatment 
supporters as the main factors that facilitated in them taking their medicines correctly, while 
the remaining participants (28%, n = 22) mentioned using reminders like cell phones and 
radio as facilitators to remembering to take their medication on time.  
 
4.7.   REASONS GIVEN FOR MISSING DOTS CLINIC APPOINTMENTS   
The main reason given by the participants (30%; n = 24) for missing their appointments was 
lack of transport money, while only 2% of the participants responded that not wanting to lose 
their day’s pay was the main reason for missing medicine refill appointments.    
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LEGEND: FORGOT = Forgot; NFW = not feeling well; SHM = still have medicine; NMFT = no money for transport; 
TWM = tired with medicine; NOTTW = did not have anyone to travel with me; NTOW = could not have time off work; 
DLDP = did not want to lose a day’s pay.  
Figure 4.1: Reasons given for missing dots clinic appointments   
 
4.8.   FACTORS AFFECTING ADHERENCE TO DOTS TREATMENTS  
Associations were tested between adherence and categorical variables. In the Chi square 
analysis, 2 × 2 tables were set up to test the associations between outcome variables (2-day 
recall; 30-day recall and pill count measures) and predictor variables (educational level; 
gender; DOTS regimens; medication side effects; distance to hospital; age and duration on 
DOTS treatment) separately. Association was tested using high and low adherence at 95% 
significance level (p < 0.05). 
 
Table 4.5 illustrates the bivariate analysis using adherence in two categories. Education status 
of participants was found to be significantly associated with adherence to DOTS (p = 0.01), 
when considering the pharmacy refill pill count as the adherence measure. Gender was found 
to be significantly associated (p = 0.03; p = 0.04) with being adherent when using the 30-day 
visual analogue and the pharmacy refill count in the dichotomous categories. Significant 
association was also found between DOTS treatment regimens and 30-day recall adherence 
measures (p = 0.002). Another significant association was found among participants’ reports 
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of medication side effects and the adherence measures of 2-day recall, 30-day recall and pill 
count with p = 0.04; p = 0.03; p = 0.05 respectively.   
 
Table 4.5: Bivariate analysis of participants’ variables using adherence in the two 
categories 
  
Optimal Adherence 
 
2 day recall            
OR (95% CI) 
[p- Value]                 
 
30 day recall            
OR (95% CI) 
[p- Value]                 
 
Pill Count            
OR (95% CI)       
[p- Value]                 
Education status 
 
Primary school/no education vs 
Higher school education 
 
 
 
0.14  (0.09-1.62) 
[0.14] 
 
 
 
0.22 (0.13-3.77) 
[0.5] 
 
 
 
0.32 (0.25- 3.77)     
[0.01] 
Gender 
 
 Female vs Male 
 
 
0.29 (0.1-1.22) 
[0.28] 
 
 
0.34 (0.09-1.66) 
[0.03] 
 
 
0.28 (0.15-1.69)      
[0.04] 
 
DOTS Regimen 
 
Isoniazid + Rifampicin + 
Pyrazinamide + Ethambutol vs 
Rifampicin + Isoniazid 
 
 
 
 
0.04 (0.01-1.12) 
[1.54] 
 
 
 
0.64 (0.22-3.16) 
[0.002] 
 
 
 
0.28 (0.18-1.39)       
[0.99] 
 
Medication Side Effect 
 
Yes vs No 
 
 
0.16 (0.11-3.72) 
[0.04] 
 
 
0.33 (0.14-1.32) 
[0.03] 
 
 
0.24 (0.2-1.28)         
[0.05] 
 
Distance travelled to clinic 
 
> 11 KM vs ≤ 11 KM 
 
 
0.4 (0.84 -1.31) 
[0.15] 
 
 
0.1 (0.78 – 1.38) 
[0.5] 
 
 
0.5 (0.78 – 1.46)     
[1.15] 
Age of Participants 
 
> 36 years vs ≤ 36 years 
 
 
0.4 (0.94 -1.06) 
[0.2] 
 
 
0.1 (0.71 – 1.32) 
[0.002] 
 
 
0.38 (0.93 – 1.07)   
[0.003] 
 
Duration on DOTS treatment 
 
> 17 weeks vs ≤ 17 weeks 
 
 
0.4 (0.70 -1.43) 
[0.09] 
 
 
0.1 (0.97 – 1.03) 
[1.75] 
 
 
0.38 (0.77 – 1.29)    
[0.75] 
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Distance to the hospital was dichotomised using the mean distance of 11 km to the hospital as 
the cut-off point. Living within a distance of 11 km from the hospital was not significantly 
associated with being adherent to TB medication when using the 3 adherence outcome 
variables as the adherence measure. Age was dichotomised by using the mean age (36 years) 
as the cut-off point. There were significant associations between age and adherence with two 
of the adherence measures (30-day recall and pill count) at p = 0.002 and p = 0.003 level of 
significance respectively. Significant association was also observed between duration of 
DOTS treatment when dichotomised using the mean treatment period (17 weeks) as the cut-
off point and any of the adherence measures.  
 
4.9. SUMMARY  
Eighty participants were included in this study, of which 76% were male. The mean 
composite adherence rate was found to be 94% while the proportion of the patients who 
achieved adherence of 95% and above was 75%. Identified barriers to adherence include lack 
of transport fare on clinic appointment days, patients not feeling well and so were not strong 
enough to attend clinic appointments and forgetfulness. The facilitators identified were 
having counselling, treatment supporters and the use of reminders such as cell phones and 
radios.  
 
Education status of participants was found to be significantly associated with adherence to 
DOTS (p = 0.01), when considering the pharmacy refill pill count as the adherence measure. 
Significant association was found between DOTS treatment regimens and 30-day recall 
adherence measures; p-values of 0.002. Significant association was found among 
participants’ reports of medication side effects and the adherence measures of 2-day recall, 
30-day recall and pill count with p = 0.04; p = 0.03; p = 0.05 respectively There were 
significant associations between age and adherence with two of the adherence measures (30-
day recall and pill count) at p = 0.002 and p = 0.003 level of significance respectively. 
Significant association was observed between duration of DOTS treatment when 
dichotomised using the mean treatment period (17 weeks) as the cut-off point and any of the 
adherence measures.  
The next chapter will discuss the key findings within the context of the study setting.  
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CHAPTER 5 
 
DISCUSSION 
As far back as four decades ago, non-adherence to TB treatment has been recognised as the 
most challenging factor against global TB control (Addington, 1979); and, non-adherence to 
TB treatment is also recognised as the main barrier to the eradication of TB malady world-
wide (Mason, 1986). Adherence to tuberculosis treatment can be particularly challenging as 
the findings of this study show.   
 
The aim of this cross-sectional study was to provide baseline data on adherence levels and 
factors associated with adherence among patients receiving DOTS from the study TB clinic. 
This chapter discusses the main findings of the study and focuses on the areas of levels of 
adherence in study participants, gender disparity in notification rate and factors influencing 
DOTS adherence which are organised according to the following categories: patient related 
factors; medication related factors; socio-economic factors; health care worker and health 
system related factors.  
 
5.1. LEVELS OF ADHERENCE IN STUDY PARTICIPANTS  
The results found a mean composite adherence of 94% using the three adherence measures: 
2-day self-report, 30-day self-report with visual analogue scale and Pharmacy pill counts. 
This means that 94% of all the pills that should have been taken by the patients were taken. 
However, this seemingly high mean adherence rate should not give rise to complacency, as 
the proportion of patients who achieved 94% and above adherence levels did not match it. 
Indeed, the proportion of patients achieving optimal adherence (> 95%) was only 75%. This 
finding highlights the disturbing fact that only three quarter of the patients on DOTS at the 
study TB clinic had sub optimal adherence rates and approximately 3% of these patients had 
adherence levels of   less than 85%. The implications for this are that a large number of 
patients on DOTS may not be getting the full benefits of their treatment and might even be 
facing the risk of developing drug resistant forms of TB.    
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As very high levels of adherence are required in order for DOTS to achieve the intended 
treatment benefits, it is critical to have a clear understanding of the factors that influence the 
patient’s ability to comply with the treatment requirements to address them and thus enhance 
adherence to DOTS (Chesney, 2000; Bangsberg et al., 2000). 
 
5.2. GENDER DISPARITY IN NOTIFICATION RATE 
Eighty patients on DOTS participated in the study with a male to female ratio of 
approximately 3:1. Research reports from other developing countries have testified to an 
increased notification rate of pulmonary TB in men (WHO, 2002). The male to female ratio 
found in this study setting is consistent with other studies where relatively high male to 
female ratio of patients on DOTS in comparison to the gender TB prevalence ratio have been 
observed (Khatri & Frieden 2000; Chakraborty 2004; Chan-Yeung et al., 2003). For example, 
the male to female ratio (3:1) of the 63 patients on DOTS at two district Hospitals in 
Indonesia (Widjanarko et al, 2009) was almost similar to the current study. From this present 
study, gender was found to be significantly associated (p = 0.03; p = 0.04) with being 
adherent when using the 30-day visual analogue and the pharmacy refill count in the 
dichotomous categories.  
 
Differential access to the health care services among females due to socioeconomic and 
cultural factors, especially in the developing countries has long been considered important 
reasons for the difference in the TB notification rates between genders. Traditionally, women 
have poorer access to money, education, information, and health (Abdool-Karim et al., 2009).  
Furthermore, it has been found in a study from South Africa that the decision regarding a 
woman’s treatment is made by the husband or senior members of the family. Women also 
have to depend on the men for their treatment-related expenses and mobility (Abdool-Karim 
et al., 2009). In a large house to house prevalence survey conducted in Bangladesh, a 
difference in the gender ratio (3:1) with an excess of cases in males was noted even after 
adjusting for confounding factors like income, awareness, and social stigma (Salim et al., 
2003). On the other hand, a comparison between age and gender-specific prevalence and 
notification rates from 29 surveys in 14 countries suggested that the reasons for a low 
notification rate for TB in females was more due to biological factors than a differential 
access of the health care (Whitacre et al., 1995). Differences in the cellular immunity and 
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antibody response following immunization increased levels of CD4+ lymphocytes than men 
(Mair, et al., 2008) and influence of sex hormones (Whitacre et al., 1995) have all been 
implicated in the decreased incidence of TB in females. Although the gender disparity was 
not directly investigated in this study, evidence from the literature suggests that there are 
multiple factors biological and social that could explain the gender disparity found in this 
study.   
      
  5.3. FACTORS INFLUENCING DOTS ADHERENCE  
Defaulting and poor treatment adherence threatens TB control, as partially treated patients are 
not cured and may develop multidrug-resistant TB. Several studies of factors associated to 
adherence have been conducted in many countries globally (Westaway and Wolmarans, 
1994; Jin et al., 1993). A systematic review of qualitative research on patient adherence to TB 
treatment identified the facilitators to completing TB treatment as structural, social, health 
service-related and personal reasons (Munro, et al., 2007). Similarly, the factors associated 
with adherence can be grouped into those related to socioeconomic circumstances and 
conditions; those related to the patients; those related to the health workers and health system; 
and those related to the disease and its treatment (WHO, 2003).  
 
5.3.1. PATIENT LEVEL FACTORS INFLUENCING ADHERENCE 
The present study explored some factors that impeded or facilitated optimal adherence to 
DOTS among the patients at the study TB clinic. All of the participants reported that they had 
missed doses of their medications at one time or the other. At the patient level, reasons given 
by the participants for missing doses varied from being away from pills (9%), forgetfulness 
(40%) and alcohol use (10%).  
 
 Reasons for missing doses  
Forgetfulness which was the main reason for missing doses may be related to being away 
from pills, which was another reason given for missing doses. Forgetfulness (i.e. forgot to 
take their medication with), which was cited by 40% of the participants, was associated with 
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the patients being away from home and thus finding themselves without their medication 
when the dose was due.  
 
The results from this study is similar to a study among patients with TB in Northwest 
Ethiopia by Adane et al (2013) where about 6% of TB patients reported that they had a 
problem of forgetfulness. From that study it was concluded that those patients who had a 
problem of forgetfulness were seven times more likely to be non-adherent than their 
counterparts (AOR: 7.04, 95% CI 1.40– 35.13). From the present study underlying reasons 
for not taking medication with them may have been forgetting, some of these issues could be 
explored further and could be addressed by patient counselling.   
 
Alcohol use as a barrier to DOTS adherence  
About 10% of the participants reported that they had missed doses of their medications at one 
time or the due to alcohol use. According to a study in Tanzania by van den Boogaard et al, 
(2011), all of the study participants suggested that alcohol abuse was the most important 
barrier to TB treatment adherence, either because they knew that alcohol and TB treatment 
cannot be taken together or because alcohol abuse made them careless about their health. 
These could also be the reasons why the participants in the current study missed their doses. 
In another study by Naidoo et al (2013), it was emphasized that alcohol use or abuse is a 
significant predictors of non-adherence common to anti-TB therapy. The authors 
recommended that a comprehensive treatment programme addressing poverty, alcohol mis-
use, tobacco use and psycho-social counselling is indicated for TB patients. The treatment 
care package needs to involve not only the health sector but other relevant government 
sectors, such as social development to address the social issues influencing treatment 
adherence.  
 
Non-adherence to treatment believed at times to be a symptom of larger social and 
psychological problems in the patient (Naidoo et al., 2013). Few unconfirmed reports have 
suggested that those with the worst records of adherence are usually former prisoners and/or 
persons affected by alcohol and drug addiction. These patterns of addiction are, in turn, taken 
as indicators of unresolved psychological illness that makes successful treatment very 
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difficult to attain (Naidoo et al., 2013, van den Boogaard et al., 2011). However, the above 
mentioned psychological related factors (i.e. alcohol and drug addictions, being a prisoner) 
could not be confirmed as factors contributing to non-adherence in this study, but 10% of the 
participants affirmed to have missed their treatment due to alcohol uses.  
 
Use of reminders as a facilitator to adherence  
In the present study, about one quarter of the participants reported that using reminders like 
cell phones and radio have facilitated them remembering to taking their medication on time 
and correctly. Similarly, personal responsibility has been found to be an important aspect of 
adherence behaviour; patients who developed their own reminders adhered readily to TB 
medication regimen (Fong, 2004). In a study by van den Boogaard et al (2011), the 
participants perceived that amongst other factors such the presence of support from family 
members and friends, and the presence of helpful health care staff, the use of reminder cues 
was a facilitator for adherence. The participants in that study mentioned several reminder 
cues that helped them to remember to take their medication. Some participants used the alarm 
of a mobile phone to inform them when the time to take the medication had reached. Others 
placed their medication bottle somewhere where it was clearly visible, to remind themselves. 
In addition, most participants carefully selected an appropriate time for medication intake 
from that study (van den Boogaard et al., 2011). Therefore, it is clear that personal reminders 
are effective facilitators for TB adherence. 
 
5.3.2. MEDICATION RELATED FACTORS  
Adverse reaction to TB medication was cited by 20% of participants in the current study as a 
reason for non-adherence. Similarly, adverse reactions to TB treatment, including hepatic 
injury, were found to contribute to non-adherence elsewhere (Munro et al., 2007; Xia and 
Zhan 2007). In the present study patients also mentioned pill burden as being one of the 
major challenges of TB treatment as a high number of pills was perceived to be associated 
with potential damage to the body and a higher risk of not tolerating the drugs. Thus, active 
surveillance of patients' adverse reactions is suggested. To minimize the impact of adverse 
reactions, it is important that health staff provide concise pre-treatment counselling to 
patients and that they manage such side-effects with timely recommendations and services.   
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5.3.3. SOCIO – ECONOMIC FACTORS  
According to Lamsal et al., (2009), poverty and TB are closely connected. They claim that 
the poor may have less flexibility regarding work and clinic attendance and less ability to pay 
for medications and transport. Nurses who took part in a phenomenological study by 
Sissolak, Marais & Mehtar (2011) conducted in Cape Town, South Africa, reported that their 
TB patients came from poor conditions and lived far from the hospital, the study found that 
these factors contributed to low adherence level to TB treatment (Sissolak, Marais & Mehtar, 
2011). 
 
Lack of food as a barrier to dots adherence 
Lack of food was the second most common reason (33%) given by the participants for 
missing doses in the present study. This barrier may be due to an increased appetite as 
patients improve with DOTS use or to non-availability of food because the patient is too 
weak to work and therefore cannot afford to buy food - an issue that can be related to 
poverty.   
 
Studies by Gebremariam et al., (2011); Maswanganyi et al., (2013); Munro et al., (2007), 
reported that the majority of patients believed that lack of food or intake of inadequate food 
was associated with more severe side effects and a difficulty to tolerate TB medications. The 
amount and quality of food needed and the degree of possible side effects were also believed 
by some patients from that study to be proportional to the medicine taken. The results of the 
present study indicate that, patients who had insufficient income mentioned the lack of food 
as a factor adversely affecting their treatment. Patients mentioned medication could be 
harmful on an empty stomach, and that it was better not to take medication if one had not 
eaten showing that they were aware of the implications of lack of food while on TB 
treatment.  
 
DOTS and nutrition have been shown to be closely related (Gebremariam et al., 2011); 
results from this study have highlighted that provision of adequate nutrition is an issue that 
requires attention in patients attending the TB Clinic.  
47 
 
Lack of transportation and distance travel to hospital as barriers to dots adherence 
Studies in Nepal (Bam & Gunneberg 2006), Uzbekhistan (Hasker et al, 2008), Malaysia 
(O‟Boyle, et al, 2002), Swaziland (Pushpananthan, Walley & Wright 2000:), and Zambia 
(Needham & Godfrey Faussett 1998) indicated that cost of transport accounts for non-
compliance to TB treatment. In the Malaysian study, cost and time of travelling to the 
treatment centre were major contributory factors associated with compliance to treatment, as 
non-compliant patients paid significantly more for transport than those compliant (O’Boyle et 
al, 2002).  
  
In the present study, the average distance travelled by the participants to arrive at the hospital 
was approximately 11 kilometres. Almost, 20% of the participants from this study travelled 
above 20 Kilometres to attend TB clinics; this could be a major contributory factor as to why 
optimal adherence could not be attained from this study’s participants.  
 
Our results suggest that addressing socio-economic factors such as providing early support in 
terms of food and financial assistance to at least cover transportation costs for patients with 
financial difficulties might facilitate adherence to DOTS treatment.  
 
5.3.4. HEALTH CARE WORKER AND HEALTH SYSTEM RELATED FACTORS 
A study in South Africa (Zwarenstein et al. 2000) found some benefit from DOT using lay 
health workers. A study in Swaziland (Wright et al. 2004) found no significant difference in 
cure rates between direct observation by community health workers (CHWs) and by family 
members. A Thai study (Kamolratanakul et al. 1999) found DOT to be effective, but they had 
adapted the original DOT model, including a choice of DOT (nearly all chose DOT by family 
members), supported by a once-weekly home visit from health workers.  
 
A review of DOT and treatment adherence (Volmink et al. 2000) emphasized the importance 
of a wide array of interventions to promote adherence, such as reminder letters, financial 
incentives and increased supervision by staff. The study observed that factors such as the 
quality of interaction between patients and supervisors may be more relevant than the DOT 
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itself, and recommended that WHO make explicit both the mixture of inputs which are 
required to improve adherence and the additional resources which successful implementation 
of DOT usually requires. 
 
Impact of treatment supporters 
The value of treatment supporters as an adherence facilitator has been reported in some 
studies (Nwokike, 2005; Nachega, 2006).  TB treatment guidelines require every patient on 
DOTS to have a mandatory treatment supporter to facilitate adherence, and clearly defined 
roles of the treatment supporter and the patient in adherence be known. In the present study, 
about 70% of the participants cited counselling and having treatment supporters as the main 
factors that encouraged them to take their medicines correctly. Similarly, in a study 
conducted in Ethiopia by Gebremariam et al, (2010), it was reported by the health 
professionals that patients who had family support and come to the clinics accompanied by 
either a family member or someone from within the community where they lived, are usually 
those who successfully complete their treatment.  
 
Our findings suggest that adherence counselling by the treatment supporter might facilitate 
adherence. Therefore, treatment supporters should endeavour to provide patients with 
uniform and complete information on DOTS. Patients should be well informed about co-
infection, side effects, pill burden and timing in the course of TB treatment. The treatment 
supporter should also discuss with the patient the importance of social support for adherence 
to treatment. Furthermore, according to the participants in this present study, apart from 
providing health education, health care staff could facilitate the patients’ adherence to 
treatment by providing reminder cues and by ensuring supervision of medication intake. The 
role of the treatment supporter should therefore not be underestimated. 
 
5.4. CONCLUSION 
Adherence to anti-TB treatment is a major determinant of treatment outcome. In developing 
countries where inequities in access to health care are high and health resources are scarce the 
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magnitude and impact of poor adherence is assumed to be higher. The implication of this is 
that many patients experience difficulties in adhering to TB treatment.  
 
The findings of this study identified barriers to adherence which include: lack of transport 
fare on clinic appointment days, patients not feeling well and so not strong enough to attend 
clinic appointments and most of the times forgetfulness. On the other hand, the facilitators of 
adherence identified from this study were counselling, treatment supporters and use of 
reminders such as cell phones and radios. Certainly the study assumes a position that there is 
an urgency to improve adherence among the patients on DOTS at the TB Clinic.  
  
As this is the first study to attempt to measure adherence and identify factors that affect 
adherence among patients on DOTS at the TB Clinic, the findings of this study provide 
baseline data that could be useful in designing practical interventions to enhance adherence in 
the Hospital and other similar settings. The study also provides groundwork for qualitative 
and quantitative studies to explore and quantify these factors further and also serves as a 
template for further investigations on influence of adherence factors on DOTS, in order to 
address problems of non-adherence to TB treatment regimen.     
 
5.5. STUDY LIMITATIONS    
The study was restricted to the western district of Pretoria and the sample size of eighty 
participants is small. Accordingly, the findings cannot be generalized to other districts or to 
the whole country. The use of structured interviews prevented the interviewers from probing 
certain aspects of patients’ behaviour and attitudes. The population for this study was 
generated from one TB clinic and therefore TB patients not registered at the participating TB 
clinic, but residing in the district, were not included in the study. Those TB patients who did 
not participate in this study might have had similar and/or different experiences affecting 
their adherence/non-adherence to TB treatment. In addition, qualitative studies would be 
beneficial to further explore the barriers and facilitators related to adherence and the ways 
that they interact to influence adherence. In addition, the clinic staff was used in 
administering questionnaires; this might have resulted in the participants being fearful and 
not willing to give accurate information, which could be a major limitation of the study. 
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Finally, it is likely that conducting the study in a hospital setting and using hospital staff 
might have inhibited some participants from expressing their personal views. To avoid this, 
the participants were reminded of the importance of truthful information in order to make 
recommendations for improvements to treatment adherence generally and that there would be 
no negative consequences to them.  
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CHAPTER 6 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
6.1. CONCLUSIONS 
Seeing that this study is the first study of its kind in Pretoria West, the findings have provided 
useful baseline data on the adherence rates and some insights into the major factors that affect 
adherence among patients on DOTS at one of the TB clinic in the region. Hence the findings 
may be useful in developing appropriate intervention strategies to improve and sustain 
optimal adherence in patients on DOTS in similar settings in South Africa. This is 
particularly important given the ongoing countrywide rollout of the DOTS programme in 
South Africa. However further qualitative and quantitative studies are required to further 
explore the factors influencing adherence in this or similar settings.  
 
The study found that the mean adherence level among the sample of 80 patients on DOTS at 
the study clinic was 94%, while the proportion of patients who achieved adherence levels of 
95% and above was 64%. Despite the reported high average adherence level, just less than 
two thirds of patients achieved optimum adherence levels; consequently, more than a third of 
the patients on DOTS at the study clinic run the risk of poor health outcomes and developing 
drug resistant forms of TB.    
 
Thus, in view of the individual and public health implications of non-adherence, these 
findings indicate an urgent need to improve adherence levels among patients on DOTS at the 
study clinic. The higher adherence levels reported in similar clinical studies in other sub-
Saharan African settings point to the feasibility of achieving greater adherence in this setting. 
In light of the scaling up of the DOTS program in South Africa, there is a need to not just 
monitor the levels of adherence, but also to identify and address factors that affect adherence 
so that an increasing number of patients on DOTS can achieve the full-intended benefits.   
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The main barriers to adherence identified in this study were forgetfulness at the patient level, 
lack of food and transport cost to attend clinic appointments at the socio-economic level. In 
addition, distance from home to the hospital was found to be significantly associated with 
adherence, with adherence decreasing with increasing distance. This barrier indicates that 
although DOTS is available at the study clinic free of charge, there are still issues of 
accessibility to many patients in terms of transport costs. Another cost related barrier to 
adherence among the patients on DOTS at the study clinic was the lack of food. Good 
nutrition is required for the restoration of the immune system, and so addressing a regular 
supply of food to patients on DOTS should be an important aspect of the DOTS Programme.  
It is therefore clear that socio-economic factors play a major role in TB treatment adherence.  
 
Related to health system factors, the role of treatment supporters and counselling were found 
to have a positive impact on adherence to DOTS in this setting. Knowledge of consequences 
of not taking DOTS as prescribed, which is closely linked with counselling, was found to be 
significantly associated with adherence in this study, highlighting the influence of the 
treatment supporters on the individual patient’s adherence behaviour. These facilitators to 
DOTS have been identified in other studies in Sub Saharan Africa and further developments 
in these services would add value to the DOTS Programme in the study clinic.   
 
6.2. RECOMMENDATIONS  
In accordance with the findings of this study, the following recommendations should be 
considered to assist in improving adherence among patients on DOTS at the study clinic.    
• The community based DOTS programme should be better implemented so that the patients 
do not have to travel so far. Also, the feasibility of mobile clinics should be explored so that 
they could also be used to reach more TB patients.   
• The on-going supportive role of the treatment supporter in adherence should be further 
encouraged and clearly defined to both the patients and the treatment supporters before 
commencement of DOTS, so as to facilitate adherence optimally. 
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It is also recommended that the TB program should ensure that treatment supporters receive 
the necessary incentives, recognition and psycho - social support to motivate them to give the 
required support to their patients. 
• A counselling protocol should be improved at the hospital, so that all patients will have the 
same access to formal counselling as their individual cases may require.   
• Alcohol abuse should be totally discouraged through adequate and timely counselling to 
patients. The complications that could arise as a result of using/abusing alcohol should be 
spelt out to the patients. They should also be referred for rehabilitation if necessary. 
• Gender imbalances i.e. women’s lack of independence in seeking health advice and 
treatment, reduced decision-making power and restricted mobility should be addressed by 
health and social development authorities as well as religious organisations in this location by 
having more awareness programs in the community. This will encourage more women to 
disclose their TB status and to adhere to DOTS treatment programmes. 
The provision of food to patients on DOTS who require such assistance should be favourably 
considered and incorporated into the DOTS programme. 
• Further studies involving both quantitative and qualitative methods, should be conducted to 
quantify and further explore the factors that influence adherence in this setting to gain a better 
understanding of these factors in order to improve the existing adherence levels. 
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APPENDICES 
 
APPENDIX 1: Questionnaire- Data Collection Tool. 
Adherence Measurement for DOTS users’ questionnaire 
Date ______________ Participant No._____ DOTS NO: ------------ 
1. Date of birth M______Y_________ 
2. Sex 
a). Male b). Female 
3. Marital Status 
a). Single b). Married /cohabiting c) Divorced d) Widowed 
4. What is the highest standard that you have passed at school? 
a) No schooling b). Grade 4 and below c). Grade 5 to 7 e). Grade 8 to 12 f) Tertiary 
5. Where do you live? -------------------------  
6. Nearest clinic/ health centre------- 
7. When did you start DOTS? M_________ Y_________ 
8. Have you experienced any side effects with TB medication? 
a). Yes b). No 
8. What do you think would happen in your body if you skipped your anti-TB 
medicine? (Please tick one) 
a). Remain sick b). Drugs won’t work later on) c). Health deteriorates d) don’t know e). Other 
(please specify) 
9. Apart from your treatment supporter, have you disclosed your TB status to anybody 
else? 
a). Yes b). No 
10. If yes to Q9 who? 
a). Brother/sister b). Parent c). Partner d) Child e). Other (please specify) 
11. Many people find it hard to take all their TB medicine exactly as prescribed. Which 
of the following reasons have caused you to skip your medicines or take them later than 
required? Please feel comfortable to answer this question truthfully (tick Max 3) 
a).Forgot b). No food c) Medicine exhausted d). Tired with the medicine e) did not have pills 
with you f). Reacted to the medicine g). Shared pills h).Feeling you had to hide medication 
from those around you i). Did not understand instructions j). Alcohol use k) Lack of 
care/support l). Others (specify please) 
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………………………………………………………………………… 
12. What is it that helps you to take your TB medicine regularly as prescribed? (Tick 
maximum 2) 
a). Treatment supporter b).counseling c). Reminders (radio, cellphone, etc.) d). Other (please 
specify) 
13. Many people find it difficult to collect their medicines or attend appointment on the 
date given by the doctor. Which of the following reasons have caused you to miss an 
appointment or not to collect your medicines? (Tick max 3) 
a.). Forgot b). Ill/ not feeling well enough c). Still had medicines left d). no money for 
transport e). Tired with medicine f). did not have anyone to travel with me g). Could not have 
time off work h). Did not want to lose a day’s pay i). Other (please specify) 
14. Can I see your medicine please? Complete names of the medicines.                        a). 
Isoniazid (H) b). Rifampicin (R) c). Streptomycin (S) d) Ethambutol (E) e). Pyrazinamide (Z) 
f). Pyridoxine 
15. 30 day recall using visual analogue. 
Ask patient to pour out one lot of beads (representing all the pills they would take in any 
given month. Note: separately for each drug). A glass full of beads is marked with a 0-10cm 
line. After pouring beads to an empty glass, estimate pills not taken by looking at the mark of 
beads remaining in the glass. 
Drug A________cm Drug B________cm Drug C______cm 
Composite_______________________cm 
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16. 2-day recall using sun and moon chart  
 
Mark “X” on each 
line the time when 
you took your 
Medicine 
Yesterday? 
6 am 7 
am 
8 
am 
9 
am 
10 
am 
11 
am 
12  1 
pm 
2 
pm 
3 
pm 
4 
pm 
5 
pm 
6 pm 7 
pm 
8 
pm 
9 
pm 
10 
pm 
11 
pm 
12  
Mor
ning 
     
Mid-
day 
     
Even
ing 
     
Night 
Drug A                    
Drug B                    
Drug C                    
Drug D                    
 
 
Mark “X” on each 
line the time when 
you took your 
Medicine the       
Day before 
Yesterday? 
6 am 7 
am 
8 
am 
9 
am 
10 
am 
11 
am 
12  1 
pm 
2 
pm 
3 
pm 
4 
pm 
5 
pm 
6 pm 7 
pm 
8 
pm 
9 
pm 
10 
pm 
11 
pm 
12  
Mor
ning 
     
Mid-
day 
     
Even
ing 
     
Night 
Drug A                    
Drug B                    
Drug C                    
Drug D                    
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17. PHARMACY REFIL RECORD pill counts 
Drug names 
(as in Q11) 
Example Drug A Drug B Drug C Drug D 
D4t     
a). Previous 
date issued 
 
2 AUG 
    
b). Quantity 
taken home 
(total) 
 
66 
    
c). Quantity 
returned 
 
11 
    
d). Date 
returned 
 
1st Sept. 
    
e). Days since 
last issued 
 
30 
    
f). Doses per 
day 
 
2 
    
g). Total 
supposed to 
take 
 
60 
    
h). Should 
have returned 
   b-g            
66 - 60 = 6 
   
i). Pills 
missed 
 c-h            
11- 6 = 5 
    
j). Percent 
adherence 
g-i/g X 100 
60-5/60X100 
    
  
…………………………………………………………………………………………………………………………………………………….. 
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APPENDIX 2: Consent form 
 
 
 
 
 
 
 
CONSENT FORM 
Title of Research Project:  
Determinants of Adherence to Tuberculosis therapy among patients receiving 
Directly Observed Treatment from a District Hospital in Pretoria, South Africa. 
 
The study has been described to me in language that I understand and I freely and 
voluntarily agree to participate.  
My questions about the study have been answered. I understand that my identity will 
not be disclosed and that I may withdraw from the study without giving a reason at 
any time and this will not negatively affect me in any way.   
Participant’s name………………………. 
Participant’s signature……………………………….            
Witness……………………………….            
Date……………………… 
 
 
FACULTY OF 
COMMUNITY AND 
HEALTH SCIENCES  
School of Public Health 
A WHO Collaborating Centre for 
Research and Training in Human 
Resources for Health 
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APPENDIX 6: Participants Information Table 
S/
N 
AGE 
(YRS) 
SEX MARIT
AL 
STATU
S 
EDU
CATI
ON 
DISTA
NCE 
(KM) 
DOTS 
DURATI
ON 
(weeks) 
SIDE 
EFFEC
T 
DRUG 
SKIP 
EFFEC
T 
TB 
DISCL
OSURE 
DRUG 
SKIP 
REASON 
DRUG 
TAKING 
FACILIT
ATOR 
APPOINT
MENT 
MISS 
DRUG 
COMBIN
ATION 
30 
DA
Y 
2 
DAY 
PHAR
M 
REFIL
L 
1 20 F S P 5 12 YES YES YES FORGOT REMIND NFW R+I 97 97 97 
2 21 M S P 8 15 YES YES YES NO FOOD SUP&CO SHM I+R+P+E 96 96 96 
3 22 M S S 14 15 YES YES YES NO FOOD SUP&CO NMFT I+R+P+E 99 99 99 
4 23 M S P 16 14 YES YES YES NO FOOD SUP&CO NMFT I+R+P+E 98 98 98 
5 24 M S S 5 15 NO YES YES REACT REMIND NFW I+R+P+E 95 95 95 
6 24 M S P 7 18 YES YES YES FORGOT REMIND TWM R+I 98 98 98 
7 21 M S P 14 16 YES YES YES REACT REMIND FORGOT I+R+P+E 92 96 92 
8 23 F S S 18 20 YES YES YES FORGOT REMIND NOTTW I+R+P+E 89 89 89 
9 22 M S P 19 13 YES YES YES FORGOT REMIND NFW I+R+P+E 95 95 95 
10 24 M S S 5 19 YES YES YES FORGOT REMIND NMFT R+I 96 96 96 
11 25 M S P 6 19 NO YES YES FORGOT REMIND FORGOT R+I 90 90 90 
12 26 M M S 12 13 YES YES YES FORGOT SUP&CO NFW R+I 99 99 99 
13 27 M M P 4 23 YES YES YES FORGOT SUP&CO NMFT R+I 95 95 95 
14 28 F M S 18 12 YES YES YES FORGOT SUP&CO FORGOT I+R+P+E 98 98 98 
15 29 M M P 30 24 NO YES YES FORGOT REMIND TWM I+R+P+E 94 95 94 
16 29 M S S 3 17 YES YES YES FORGOT SUP&CO NMFT R+I 97 97 97 
17 29 M M P 25 22 YES YES YES FORGOT SUP&CO NOTTW I+R+P+E 91 95 91 
18 25 M M S 4 22 YES YES YES FORGOT REMIND NFW I+R+P+E 98 98 98 
19 27 M M N 7 16 YES YES YES REACT SUP&CO NMFT R+I 92 95 92 
20 26 M S P 2 18 YES YES YES NO FOOD SUP&CO TWM I+R+P+E 95 95 95 
21 28 F M S 11 19 YES YES YES REACT REMIND SHM R+I 84 95 80 
22 29 M D P 1 18 NO YES YES REACT SUP&CO NTOW I+R+P+E 95 95 95 
23 26 M S S 21 17 YES YES YES FORGOT SUP&CO NFW I+R+P+E 80 95 84 
24 30 F M P 5 12 YES YES YES REACT SUP&CO NMFT R+I 96 96 96 
25 31 M D P 8 23 NO YES YES REACT SUP&CO TWM I+R+P+E 99 99 99 
26 32 M M P 3 23 YES YES YES NO PILLS SUP&CO NFW R+I 80 84 80 
27 33 M S P 24 16 YES YES YES FORGOT SUP&CO NOTTW I+R+P+E 96 96 96 
28 34 M D P 2 21 NO YES YES NO PILLS SUP&CO NFW I+R+P+E 80 96 84 
29 34 M D S 19 14 YES YES YES NO PILLS SUP&CO FORGOT R+I 95 95 95 
30 33 M S P 9 20 YES YES YES NO FOOD SUP&CO TWM I+R+P+E 80 98 82 
31 32 M D S 4 22 NO YES YES NO PILLS SUP&CO NFW I+R+P+E 98 98 98 
32 31 M S S 5 15 YES YES YES ALCOHL REMIND NMFT R+I 98 98 98 
33 33 M D P 24 19 YES YES YES FORGOT SUP&CO NMFT I+R+P+E 80 98 83 
34 30 M M S 10 19 YES YES YES FORGOT SUP&CO TWM I+R+P+E 97 97 97 
35 35 F M P 20 17 YES YES YES FORGOT SUP&CO FORGOT R+I 83 80 95 
36 36 M D N 24 12 NO YES YES FORGOT REMIND DLDP I+R+P+E 99 99 99 
37 37 M M S 24 21 YES YES YES FORGOT SUP&CO NFW I+R+P+E 80 99 84 
38 38 M M S 2 20 YES YES YES REACT SUP&CO NTOW R+I 97 97 97 
39 39 M M N 27 25 YES YES YES NO FOOD SUP&CO NMFT I+R+P+E 84 95 84 
40 35 F D S 23 15 YES YES YES REACT SUP&CO DLDP I+R+P+E 95 95 95 
41 36 M M P 15 18 YES YES YES REACT REMIND NFW R+I 83 95 99 
42 37 M M S 21 18 YES YES YES FORGOT SUP&CO NMFT I+R+P+E 95 95 95 
43 38 M D P 4 17 YES YES YES FORGOT SUP&CO NOTTW I+R+P+E 95 95 95 
44 39 M M S 23 18 YES YES YES FORGOT SUP&CO NFW I+R+P+E 91 99 91 
45 35 M M S 25 12 YES YES YES FORGOT SUP&CO NMFT R+I 90 94 90 
46 40 F D P 14 18 YES YES YES ALCOHL SUP&CO NTOW I+R+P+E 96 96 96 
47 41 M W S 5 17 NO YES YES NO FOOD REMIND FORGOT R+I 89 89 89 
48 42 M W P 22 12 YES YES YES ALCOHL SUP&CO NTOW I+R+P+E 98 98 98 
49 43 M M S 9 18 YES YES YES FORGOT SUP&CO SHM I+R+P+E 97 97 97 
50 44 M D P 10 18 YES YES YES ALCOHL REMIND NMFT I+R+P+E 82 95 82 
51 43 M M S 5 16 YES YES YES NO FOOD SUP&CO NOTTW I+R+P+E 96 96 96 
52 42 M M S 9 19 YES YES YES ALCOHL SUP&CO FORGOT R+I 97 97 97 
53 41 M W N 21 18 YES YES YES FORGOT REMIND FORGOT I+R+P+E 92 95 92 
54 40 M D P 13 14 YES YES YES REACT SUP&CO TWM I+R+P+E 99 99 99 
55 41 M M P 5 20 NO YES YES NO FOOD SUP&CO NFW I+R+P+E 94 95 94 
56 42 M M P 19 17 YES YES YES ALCOHL SUP&CO NMFT R+I 96 96 96 
57 43 M W S 8 13 YES YES YES FORGOT SUP&CO NMFT I+R+P+E 96 96 96 
58 44 M M P 25 15 YES YES YES REACT REMIND NFW I+R+P+E 90 90 90 
59 43 F D P 3 19 YES YES YES ALCOHL SUP&CO NMFT R+I 96 96 96 
60 42 M M P 20 25 NO YES YES FORGOT SUP&CO NMFT I+R+P+E 98 98 98 
61 41 M D S 18 14 YES YES YES REACT SUP&CO TWM R+I 95 95 95 
62 40 F M N 4 23 YES YES YES NO PILLS REMIND FORGOT I+R+P+E 90 91 90 
63 40 M M S 12 13 YES YES YES NO FOOD SUP&CO NMFT I+R+P+E 98 98 98 
64 40 F D P 2 25 YES YES YES ALCOHL SUP&CO NMFT R+I 95 95 95 
65 41 M M P 17 12 YES YES YES NO FOOD SUP&CO NMFT I+R+P+E 90 95 90 
66 43 F M S 1 15 NO YES YES REACT SUP&CO NFW I+R+P+E 80 94 81 
67 44 M D P 7 24 YES YES YES FORGOT REMIND NMFT I+R+P+E 90 94 90 
68 44 F W P 3 18 NO YES YES NO FOOD SUP&CO NMFT R+I 97 97 97 
69 49 F W S 4 24 YES YES YES NO PILLS SUP&CO NMFT I+R+P+E 89 99 89 
70 46 M D P 10 12 YES YES YES FORGOT SUP&CO NMFT I+R+P+E 88 95 88 
71 45 F W N 10 19 YES YES YES REACT SUP&CO FORGOT R+I 95 95 95 
72 45 M W P 4 16 YES YES YES NO PILLS SUP&CO FORGOT I+R+P+E 87 95 87 
73 48 M D P 2 20 YES YES YES NO FOOD SUP&CO FORGOT I+R+P+E 99 99 99 
74 47 F W S 5 15 YES YES YES REACT SUP&CO SHM I+R+P+E 90 95 90 
75 46 M W N 11 13 YES YES YES FORGOT REMIND NFW R+I 95 95 95 
92 
 
76 46 F D P 2 14 YES YES YES NO FOOD SUP&CO SHM R+I 92 95 92 
77 48 M D P 6 12 YES YES YES REACT SUP&CO FORGOT I+R+P+E 97 97 97 
78 49 F D N 5 14 YES YES YES FORGOT SUP&CO NFW R+I 98 98 98 
79 54 F D N 2 12 YES YES YES NO FOOD REMIND SHM I+R+P+E 96 96 96 
80 52 M D P 5 13 YES YES YES NO FOOD SUP&CO FORGOT R+I 95 95 95 
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